Global Oncolytic Virus Cancer Immunotherapy Market By Virus Type (Adenovirus, Herpes Simplex Virus, Maraba Virus, Measles, Newcastle Disease Virus, Picornavirus, Reovirus, Vaccinia Virus, Vesicular Stomatitis Virus, Coxsackie Virus, Others); By Clinical Trial Phases (Pre-clinical Phase, Phase I, Phase II, Phase III, Phase IV); By Immunotherapy Type (Immune Checkpoint Inhibitors, T-cell Transfer Therapy, Monoclonal Antibodies, Treatment Vaccines, Immune System Modulators, Combination Types); By Antitumor Modes of Action for OVs (Oncolysis, Transgene expression, Vascular Collapse, Antitumor Immunity); By Route (Intratumoral Dose, Intravenous); By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Appendiceal Cancer, Others); By End Users (Hospitals, Clinics, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Global oncolytic virus cancer immunotherapy market was valued US$ 99.8 Mn by 2021 and is growing at an estimated CAGR of 13.7% over the forecast period. Number of people suffering from chronic diseases like cancer are on a rise. Several factors are affecting this which includes sedentary lifestyle, bad eating habits etc. In order to treat cancer, hospitals and specialty clinics are using several therapies like chemo and radiation. One such therapy that is rapidly gaining popularity is oncolytic virus cancer immunotherapy. This virus primarily infects the cancer cells and then kills them. As soon as infected cells of cancer are killed, new infectious virus particles are released in an attempt to get rid of the remaining tumour. Hence the global oncolytic virus cancer immunotherapy market is growing significantly.
Virus Type Outlook
On the basis of virus type, the global oncolytic virus cancer immunotherapy market has been divided into adenovirus, herpes simplex virus, maraba virus, measles, Newcastle disease virus, picornavirus, vaccinia virus, vesicular stomatitis virus, coxsackie virus and others. Maraba happens to one of the potent oncolytic virus which can create antitumor immunity that too in safe conditions. Meanwhile, the herpes simplex virus is the one that causes herpes in mouth and genitals.
Global Oncolytic Virus Cancer Immunotherapy Market Revenue & Forecast, (US$ Million), 2022 – 2030
Clinical Trial Phases Outlook
On the basis of clinical trial phases, the global oncolytic virus cancer Immunotherapy Market has been segmented into pre-clinical phase, phase I, phase II, phase III and phase IV. The efficacy of any therapy or drug is determined before they are clinically tested and this is the reason why the pre-clinical segment accounts for maximum revenue generated by this market.
Immunotherapy Type Outlook
On the basis of immunotherapy type, the global oncolytic virus cancer immunotherapy market has been categorised into immune checkpoint inhibitors, T-cell transfer therapy, monoclonal antibodies, treatment vaccines, immune system modulators and combination types. Monoclonal antibodies are those antibodies that are produced by one clone of cells and comprise of identical antibody molecules. These antibodies are rampantly being used in the treatment of cancer.
Antitumor Modes of Action for OVs Outlook
On the basis of the antitumor modes of action for OVs, the global oncolytic virus cancer immunotherapy market has been divided into oncolysis, transgene expression, vascular collapse and antitumor immunity. This type of virus is being administered through various modes, but oncolysis mode is preferred the most.
Route Outlook
On the basis of the route, the global oncolytic virus cancer immunotherapy market has been segmented into intratumoral dose and intravenous. Intravenous route is the easiest way of administering oncolytic virus in order to treat the dreadful cancer.
Cancer Type Outlook
On the basis of the cancer type, the global oncolytic virus cancer immunotherapy market has been bifurcated into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, ovarian cancer, pancreatic cancer, appendiceal cancer, and others. It has been observed that this therapy has been extremely effective when used in early stage of cancer, irrespective of type.
End Users Outlook
On the basis of the end users, the global oncolytic virus cancer immunotherapy market has been divided into hospitals, clinics and others. The hospitals segment account for maximum amount of money minted by this market.
Region Outlook
The region of the North America dominated in terms of registering highest sales for the global oncolytic virus cancer immunotherapy market. This is due to presence of top-class medical facilities in countries like Canada and the United States.
Competitive Landscape
The report provides both, qualitative and quantitative research of global oncolytic virus cancer immunotherapy market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Key players operating in the global oncolytic virus cancer immunotherapy market are mentioned:
- Astra Zeneca
- Daiichi Sankyo Company
- Genelux Corporation
- Lokon Pharma AB
- Merck & Co. (Viralytics)
- Oncolytics Biotech, Inc.
- PFIZER with WESTERN ONCOLYTICS
- Psivac Ltd.
- TNK Therapeutics, Inc (Virttu Biologics)
- Transgene/ Sillajen
- Wellstat Biologics
- Other Market Participants
Global Oncolytic Virus Cancer Immunotherapy Market
By Virus Type
- Adenovirus
- Herpes Simplex Virus
- Maraba Virus
- Measles
- Newcastle Disease Virus
- Picornavirus
- Reovirus
- Vaccinia Virus
- Vesicular Stomatitis Virus
- Coxsackie Virus
- Others
By Clinical Trial Phases
- Pre-Clinical Phase
- Phase I
- Phase II
- Phase III
- Phase IV
By Immunotherapy Type
- Immune Checkpoint Inhibitors
- T-cell Transfer Therapy
- Monoclonal Antibodies
- Treatment Vaccines
- Immune System Modulators
- Combination Types
By Antitumor Modes of Action for OVs
- Oncolysis
- Transgene expression
- Vascular Collapse
- Antitumor Immunity
By Route
- Intratumoral Dose
- Intravenous
By Cancer Type
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Head and Neck Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Appendiceal Cancer
- Others
By End Users
- Hospitals
- Clinics
- Others
By Region
- North America
- S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2020
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 – 2030
2. Key Target Audiences
3. Research Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Oncolytic Virus Cancer Immunotherapy Market
6. Market Synopsis: Oncolytic Virus Cancer Immunotherapy Market
7. Oncolytic Virus Cancer Immunotherapy Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in Oncolytic Virus Cancer Immunotherapy Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators: Oncolytic Virus Cancer Immunotherapy Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Oncolytic Virus Cancer Immunotherapy Market
8. Global Oncolytic Virus Cancer Immunotherapy Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn)
8.2. Global Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
8.2.1. Adenovirus
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 – 2021
8.2.1.3. Market Forecast, 2022 – 2030
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market Estimation, 2015 – 2021
8.2.1.5.1.2. Market Forecast, 2022 – 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market Estimation, 2015 – 2021
8.2.1.5.2.2. Market Forecast, 2022 – 2030
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market Estimation, 2015 – 2021
8.2.1.5.3.2. Market Forecast, 2022 – 2030
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market Estimation, 2015 – 2021
8.2.1.5.4.2. Market Forecast, 2022 – 2030
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market Estimation, 2015 – 2021
8.2.1.5.5.2. Market Forecast, 2022 – 2030
8.2.2. Herpes Simplex Virus
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 – 2021
8.2.2.3. Market Forecast, 2022 – 2030
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market Estimation, 2015 – 2021
8.2.2.5.1.2. Market Forecast, 2022 – 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market Estimation, 2015 – 2021
8.2.2.5.2.2. Market Forecast, 2022 – 2030
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market Estimation, 2015 – 2021
8.2.2.5.3.2. Market Forecast, 2022 – 2030
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market Estimation, 2015 – 2021
8.2.2.5.4.2. Market Forecast, 2022 – 2030
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market Estimation, 2015 – 2021
8.2.2.5.5.2. Market Forecast, 2022 – 2030
8.2.3. Maraba Virus
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 – 2021
8.2.3.3. Market Forecast, 2022 – 2030
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market Estimation, 2015 – 2021
8.2.3.5.1.2. Market Forecast, 2022 – 2030
8.2.3.5.2. Europe
8.2.3.5.2.1. Market Estimation, 2015 – 2021
8.2.3.5.2.2. Market Forecast, 2022 – 2030
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market Estimation, 2015 – 2021
8.2.3.5.3.2. Market Forecast, 2022 – 2030
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market Estimation, 2015 – 2021
8.2.3.5.4.2. Market Forecast, 2022 – 2030
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market Estimation, 2015 – 2021
8.2.3.5.5.2. Market Forecast, 2022 – 2030
8.2.4. Measles
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 – 2021
8.2.4.3. Market Forecast, 2022 – 2030
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market Estimation, 2015 – 2021
8.2.4.5.1.2. Market Forecast, 2022 – 2030
8.2.4.5.2. Europe
8.2.4.5.2.1. Market Estimation, 2015 – 2021
8.2.4.5.2.2. Market Forecast, 2022 – 2030
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market Estimation, 2015 – 2021
8.2.4.5.3.2. Market Forecast, 2022 – 2030
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market Estimation, 2015 – 2021
8.2.4.5.4.2. Market Forecast, 2022 – 2030
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market Estimation, 2015 – 2021
8.2.4.5.5.2. Market Forecast, 2022 – 2030
8.2.5. Newcastle Disease Virus
8.2.5.1. Definition
8.2.5.2. Market Estimation and Penetration, 2015 – 2021
8.2.5.3. Market Forecast, 2022 – 2030
8.2.5.4. Compound Annual Growth Rate (CAGR)
8.2.5.5. Regional Bifurcation
8.2.5.5.1. North America
8.2.5.5.1.1. Market Estimation, 2015 – 2021
8.2.5.5.1.2. Market Forecast, 2022 – 2030
8.2.5.5.2. Europe
8.2.5.5.2.1. Market Estimation, 2015 – 2021
8.2.5.5.2.2. Market Forecast, 2022 – 2030
8.2.5.5.3. Asia Pacific
8.2.5.5.3.1. Market Estimation, 2015 – 2021
8.2.5.5.3.2. Market Forecast, 2022 – 2030
8.2.5.5.4. Middle East and Africa
8.2.5.5.4.1. Market Estimation, 2015 – 2021
8.2.5.5.4.2. Market Forecast, 2022 – 2030
8.2.5.5.5. Latin America
8.2.5.5.5.1. Market Estimation, 2015 – 2021
8.2.5.5.5.2. Market Forecast, 2022 – 2030
8.2.6. Picornavirus
8.2.6.1. Definition
8.2.6.2. Market Estimation and Penetration, 2015 – 2021
8.2.6.3. Market Forecast, 2022 – 2030
8.2.6.4. Compound Annual Growth Rate (CAGR)
8.2.6.5. Regional Bifurcation
8.2.6.5.1. North America
8.2.6.5.1.1. Market Estimation, 2015 – 2021
8.2.6.5.1.2. Market Forecast, 2022 – 2030
8.2.6.5.2. Europe
8.2.6.5.2.1. Market Estimation, 2015 – 2021
8.2.6.5.2.2. Market Forecast, 2022 – 2030
8.2.6.5.3. Asia Pacific
8.2.6.5.3.1. Market Estimation, 2015 – 2021
8.2.6.5.3.2. Market Forecast, 2022 – 2030
8.2.6.5.4. Middle East and Africa
8.2.6.5.4.1. Market Estimation, 2015 – 2021
8.2.6.5.4.2. Market Forecast, 2022 – 2030
8.2.6.5.5. Latin America
8.2.6.5.5.1. Market Estimation, 2015 – 2021
8.2.6.5.5.2. Market Forecast, 2022 – 2030
8.2.7. Reovirus
8.2.7.1. Definition
8.2.7.2. Market Estimation and Penetration, 2015 – 2021
8.2.7.3. Market Forecast, 2022 – 2030
8.2.7.4. Compound Annual Growth Rate (CAGR)
8.2.7.5. Regional Bifurcation
8.2.7.5.1. North America
8.2.7.5.1.1. Market Estimation, 2015 – 2021
8.2.7.5.1.2. Market Forecast, 2022 – 2030
8.2.7.5.2. Europe
8.2.7.5.2.1. Market Estimation, 2015 – 2021
8.2.7.5.2.2. Market Forecast, 2022 – 2030
8.2.7.5.3. Asia Pacific
8.2.7.5.3.1. Market Estimation, 2015 – 2021
8.2.7.5.3.2. Market Forecast, 2022 – 2030
8.2.7.5.4. Middle East and Africa
8.2.7.5.4.1. Market Estimation, 2015 – 2021
8.2.7.5.4.2. Market Forecast, 2022 – 2030
8.2.7.5.5. Latin America
8.2.7.5.5.1. Market Estimation, 2015 – 2021
8.2.7.5.5.2. Market Forecast, 2022 – 2030
8.2.8. Vaccinia Virus
8.2.8.1. Definition
8.2.8.2. Market Estimation and Penetration, 2015 – 2021
8.2.8.3. Market Forecast, 2022 – 2030
8.2.8.4. Compound Annual Growth Rate (CAGR)
8.2.8.5. Regional Bifurcation
8.2.8.5.1. North America
8.2.8.5.1.1. Market Estimation, 2015 – 2021
8.2.8.5.1.2. Market Forecast, 2022 – 2030
8.2.8.5.2. Europe
8.2.8.5.2.1. Market Estimation, 2015 – 2021
8.2.8.5.2.2. Market Forecast, 2022 – 2030
8.2.8.5.3. Asia Pacific
8.2.8.5.3.1. Market Estimation, 2015 – 2021
8.2.8.5.3.2. Market Forecast, 2022 – 2030
8.2.8.5.4. Middle East and Africa
8.2.8.5.4.1. Market Estimation, 2015 – 2021
8.2.8.5.4.2. Market Forecast, 2022 – 2030
8.2.8.5.5. Latin America
8.2.8.5.5.1. Market Estimation, 2015 – 2021
8.2.8.5.5.2. Market Forecast, 2022 – 2030
8.2.9. Vesicular Stomatitis Virus
8.2.9.1. Definition
8.2.9.2. Market Estimation and Penetration, 2015 – 2021
8.2.9.3. Market Forecast, 2022 – 2030
8.2.9.4. Compound Annual Growth Rate (CAGR)
8.2.9.5. Regional Bifurcation
8.2.9.5.1. North America
8.2.9.5.1.1. Market Estimation, 2015 – 2021
8.2.9.5.1.2. Market Forecast, 2022 – 2030
8.2.9.5.2. Europe
8.2.9.5.2.1. Market Estimation, 2015 – 2021
8.2.9.5.2.2. Market Forecast, 2022 – 2030
8.2.9.5.3. Asia Pacific
8.2.9.5.3.1. Market Estimation, 2015 – 2021
8.2.9.5.3.2. Market Forecast, 2022 – 2030
8.2.9.5.4. Middle East and Africa
8.2.9.5.4.1. Market Estimation, 2015 – 2021
8.2.9.5.4.2. Market Forecast, 2022 – 2030
8.2.9.5.5. Latin America
8.2.9.5.5.1. Market Estimation, 2015 – 2021
8.2.9.5.5.2. Market Forecast, 2022 – 2030
8.2.10. Coxsackie Virus
8.2.10.1. Definition
8.2.10.2. Market Estimation and Penetration, 2015 – 2021
8.2.10.3. Market Forecast, 2022 – 2030
8.2.10.4. Compound Annual Growth Rate (CAGR)
8.2.10.5. Regional Bifurcation
8.2.10.5.1. North America
8.2.10.5.1.1. Market Estimation, 2015 – 2021
8.2.10.5.1.2. Market Forecast, 2022 – 2030
8.2.10.5.2. Europe
8.2.10.5.2.1. Market Estimation, 2015 – 2021
8.2.10.5.2.2. Market Forecast, 2022 – 2030
8.2.10.5.3. Asia Pacific
8.2.10.5.3.1. Market Estimation, 2015 – 2021
8.2.10.5.3.2. Market Forecast, 2022 – 2030
8.2.10.5.4. Middle East and Africa
8.2.10.5.4.1. Market Estimation, 2015 – 2021
8.2.10.5.4.2. Market Forecast, 2022 – 2030
8.2.10.5.5. Latin America
8.2.10.5.5.1. Market Estimation, 2015 – 2021
8.2.10.5.5.2. Market Forecast, 2022 – 2030
8.2.11. Others
8.2.11.1. Definition
8.2.11.2. Market Estimation and Penetration, 2015 – 2021
8.2.11.3. Market Forecast, 2022 – 2030
8.2.11.4. Compound Annual Growth Rate (CAGR)
8.2.11.5. Regional Bifurcation
8.2.11.5.1. North America
8.2.11.5.1.1. Market Estimation, 2015 – 2021
8.2.11.5.1.2. Market Forecast, 2022 – 2030
8.2.11.5.2. Europe
8.2.11.5.2.1. Market Estimation, 2015 – 2021
8.2.11.5.2.2. Market Forecast, 2022 – 2030
8.2.11.5.3. Asia Pacific
8.2.11.5.3.1. Market Estimation, 2015 – 2021
8.2.11.5.3.2. Market Forecast, 2022 – 2030
8.2.11.5.4. Middle East and Africa
8.2.11.5.4.1. Market Estimation, 2015 – 2021
8.2.11.5.4.2. Market Forecast, 2022 – 2030
8.2.11.5.5. Latin America
8.2.11.5.5.1. Market Estimation, 2015 – 2021
8.2.11.5.5.2. Market Forecast, 2022 – 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Virus Type
9. Global Oncolytic Virus Cancer Immunotherapy Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
9.2.1. Phase 0
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 – 2021
9.2.1.3. Market Forecast, 2022 – 2030
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market Estimation, 2015 – 2021
9.2.1.5.1.2. Market Forecast, 2022 – 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market Estimation, 2015 – 2021
9.2.1.5.2.2. Market Forecast, 2022 – 2030
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market Estimation, 2015 – 2021
9.2.1.5.3.2. Market Forecast, 2022 – 2030
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market Estimation, 2015 – 2021
9.2.1.5.4.2. Market Forecast, 2022 – 2030
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market Estimation, 2015 – 2021
9.2.1.5.5.2. Market Forecast, 2022 – 2030
9.2.2. Phase I
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 – 2021
9.2.2.3. Market Forecast, 2022 – 2030
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market Estimation, 2015 – 2021
9.2.2.5.1.2. Market Forecast, 2022 – 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market Estimation, 2015 – 2021
9.2.2.5.2.2. Market Forecast, 2022 – 2030
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market Estimation, 2015 – 2021
9.2.2.5.3.2. Market Forecast, 2022 – 2030
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market Estimation, 2015 – 2021
9.2.2.5.4.2. Market Forecast, 2022 – 2030
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market Estimation, 2015 – 2021
9.2.2.5.5.2. Market Forecast, 2022 – 2030
9.2.3. Phase II
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 – 2021
9.2.3.3. Market Forecast, 2022 – 2030
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market Estimation, 2015 – 2021
9.2.3.5.1.2. Market Forecast, 2022 – 2030
9.2.3.5.2. Europe
9.2.3.5.2.1. Market Estimation, 2015 – 2021
9.2.3.5.2.2. Market Forecast, 2022 – 2030
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market Estimation, 2015 – 2021
9.2.3.5.3.2. Market Forecast, 2022 – 2030
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market Estimation, 2015 – 2021
9.2.3.5.4.2. Market Forecast, 2022 – 2030
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market Estimation, 2015 – 2021
9.2.3.5.5.2. Market Forecast, 2022 – 2030
9.2.4. Phase III
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 – 2021
9.2.4.3. Market Forecast, 2022 – 2030
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market Estimation, 2015 – 2021
9.2.4.5.1.2. Market Forecast, 2022 – 2030
9.2.4.5.2. Europe
9.2.4.5.2.1. Market Estimation, 2015 – 2021
9.2.4.5.2.2. Market Forecast, 2022 – 2030
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market Estimation, 2015 – 2021
9.2.4.5.3.2. Market Forecast, 2022 – 2030
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market Estimation, 2015 – 2021
9.2.4.5.4.2. Market Forecast, 2022 – 2030
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market Estimation, 2015 – 2021
9.2.4.5.5.2. Market Forecast, 2022 – 2030
9.2.5. Phase IV
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2015 – 2021
9.2.5.3. Market Forecast, 2022 – 2030
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market Estimation, 2015 – 2021
9.2.5.5.1.2. Market Forecast, 2022 – 2030
9.2.5.5.2. Europe
9.2.5.5.2.1. Market Estimation, 2015 – 2021
9.2.5.5.2.2. Market Forecast, 2022 – 2030
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market Estimation, 2015 – 2021
9.2.5.5.3.2. Market Forecast, 2022 – 2030
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market Estimation, 2015 – 2021
9.2.5.5.4.2. Market Forecast, 2022 – 2030
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market Estimation, 2015 – 2021
9.2.5.5.5.2. Market Forecast, 2022 – 2030
9.3. Key Segment for Channeling Investments
9.3.1. By Clinical Trial Phases
10. Global Oncolytic Virus Cancer Immunotherapy Market Analysis and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
10.2.1. Immune Checkpoint Inhibitors
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 – 2021
10.2.1.3. Market Forecast, 2022 – 2030
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2015 – 2021
10.2.1.5.1.2. Market Forecast, 2022 – 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2015 – 2021
10.2.1.5.2.2. Market Forecast, 2022 – 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015 – 2021
10.2.1.5.3.2. Market Forecast, 2022 – 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2015 – 2021
10.2.1.5.4.2. Market Forecast, 2022 – 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2015 – 2021
10.2.1.5.5.2. Market Forecast, 2022 – 2030
10.2.2. T-cell Transfer Therapy
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 – 2021
10.2.2.3. Market Forecast, 2022 – 2030
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 – 2021
10.2.2.5.1.2. Market Forecast, 2022 – 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 – 2021
10.2.2.5.2.2. Market Forecast, 2022 – 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 – 2021
10.2.2.5.3.2. Market Forecast, 2022 – 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 – 2021
10.2.2.5.4.2. Market Forecast, 2022 – 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 – 2021
10.2.2.5.5.2. Market Forecast, 2022 – 2030
10.2.3. Monoclonal Antibodies
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 – 2021
10.2.3.3. Market Forecast, 2022 – 2030
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market Estimation, 2015 – 2021
10.2.3.5.1.2. Market Forecast, 2022 – 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market Estimation, 2015 – 2021
10.2.3.5.2.2. Market Forecast, 2022 – 2030
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market Estimation, 2015 – 2021
10.2.3.5.3.2. Market Forecast, 2022 – 2030
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market Estimation, 2015 – 2021
10.2.3.5.4.2. Market Forecast, 2022 – 2030
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market Estimation, 2015 – 2021
10.2.3.5.5.2. Market Forecast, 2022 – 2030
10.2.4. Treatment Vaccines
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 – 2021
10.2.4.3. Market Forecast, 2022 – 2030
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market Estimation, 2015 – 2021
10.2.4.5.1.2. Market Forecast, 2022 – 2030
10.2.4.5.2. Europe
10.2.4.5.2.1. Market Estimation, 2015 – 2021
10.2.4.5.2.2. Market Forecast, 2022 – 2030
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market Estimation, 2015 – 2021
10.2.4.5.3.2. Market Forecast, 2022 – 2030
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market Estimation, 2015 – 2021
10.2.4.5.4.2. Market Forecast, 2022 – 2030
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market Estimation, 2015 – 2021
10.2.4.5.5.2. Market Forecast, 2022 – 2030
10.2.5. Immune System Modulators
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2015 – 2021
10.2.5.3. Market Forecast, 2022 – 2030
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market Estimation, 2015 – 2021
10.2.5.5.1.2. Market Forecast, 2022 – 2030
10.2.5.5.2. Europe
10.2.5.5.2.1. Market Estimation, 2015 – 2021
10.2.5.5.2.2. Market Forecast, 2022 – 2030
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market Estimation, 2015 – 2021
10.2.5.5.3.2. Market Forecast, 2022 – 2030
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market Estimation, 2015 – 2021
10.2.5.5.4.2. Market Forecast, 2022 – 2030
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market Estimation, 2015 – 2021
10.2.5.5.5.2. Market Forecast, 2022 – 2030
10.2.6. Combination Types
10.2.6.1. Definition
10.2.6.2. Market Estimation and Penetration, 2015 – 2021
10.2.6.3. Market Forecast, 2022 – 2030
10.2.6.4. Compound Annual Growth Rate (CAGR)
10.2.6.5. Regional Bifurcation
10.2.6.5.1. North America
10.2.6.5.1.1. Market Estimation, 2015 – 2021
10.2.6.5.1.2. Market Forecast, 2022 – 2030
10.2.6.5.2. Europe
10.2.6.5.2.1. Market Estimation, 2015 – 2021
10.2.6.5.2.2. Market Forecast, 2022 – 2030
10.2.6.5.3. Asia Pacific
10.2.6.5.3.1. Market Estimation, 2015 – 2021
10.2.6.5.3.2. Market Forecast, 2022 – 2030
10.2.6.5.4. Middle East and Africa
10.2.6.5.4.1. Market Estimation, 2015 – 2021
10.2.6.5.4.2. Market Forecast, 2022 – 2030
10.2.6.5.5. Latin America
10.2.6.5.5.1. Market Estimation, 2015 – 2021
10.2.6.5.5.2. Market Forecast, 2022 – 2030
10.3. Key Segment for Channeling Investments
10.3.1. By Immunotherapy Type
11. Global Oncolytic Virus Cancer Immunotherapy Market Analysis and Forecasts, 2022 – 2030
11.1. Overview
11.2. Global Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
11.2.1. Oncolysis
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 – 2021
11.2.1.3. Market Forecast, 2022 – 2030
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market Estimation, 2015 – 2021
11.2.1.5.1.2. Market Forecast, 2022 – 2030
11.2.1.5.2. Europe
11.2.1.5.2.1. Market Estimation, 2015 – 2021
11.2.1.5.2.2. Market Forecast, 2022 – 2030
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market Estimation, 2015 – 2021
11.2.1.5.3.2. Market Forecast, 2022 – 2030
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market Estimation, 2015 – 2021
11.2.1.5.4.2. Market Forecast, 2022 – 2030
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market Estimation, 2015 – 2021
11.2.1.5.5.2. Market Forecast, 2022 – 2030
11.2.2. Transgene Expression
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 – 2021
11.2.2.3. Market Forecast, 2022 – 2030
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market Estimation, 2015 – 2021
11.2.2.5.1.2. Market Forecast, 2022 – 2030
11.2.2.5.2. Europe
11.2.2.5.2.1. Market Estimation, 2015 – 2021
11.2.2.5.2.2. Market Forecast, 2022 – 2030
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market Estimation, 2015 – 2021
11.2.2.5.3.2. Market Forecast, 2022 – 2030
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market Estimation, 2015 – 2021
11.2.2.5.4.2. Market Forecast, 2022 – 2030
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market Estimation, 2015 – 2021
11.2.2.5.5.2. Market Forecast, 2022 – 2030
11.2.3. Vascular Collapse
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 – 2021
11.2.3.3. Market Forecast, 2022 – 2030
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market Estimation, 2015 – 2021
11.2.3.5.1.2. Market Forecast, 2022 – 2030
11.2.3.5.2. Europe
11.2.3.5.2.1. Market Estimation, 2015 – 2021
11.2.3.5.2.2. Market Forecast, 2022 – 2030
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market Estimation, 2015 – 2021
11.2.3.5.3.2. Market Forecast, 2022 – 2030
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market Estimation, 2015 – 2021
11.2.3.5.4.2. Market Forecast, 2022 – 2030
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market Estimation, 2015 – 2021
11.2.3.5.5.2. Market Forecast, 2022 – 2030
11.2.4. Antitumor Immunity
11.2.4.1. Definition
11.2.4.2. Market Estimation and Penetration, 2015 – 2021
11.2.4.3. Market Forecast, 2022 – 2030
11.2.4.4. Compound Annual Growth Rate (CAGR)
11.2.4.5. Regional Bifurcation
11.2.4.5.1. North America
11.2.4.5.1.1. Market Estimation, 2015 – 2021
11.2.4.5.1.2. Market Forecast, 2022 – 2030
11.2.4.5.2. Europe
11.2.4.5.2.1. Market Estimation, 2015 – 2021
11.2.4.5.2.2. Market Forecast, 2022 – 2030
11.2.4.5.3. Asia Pacific
11.2.4.5.3.1. Market Estimation, 2015 – 2021
11.2.4.5.3.2. Market Forecast, 2022 – 2030
11.2.4.5.4. Middle East and Africa
11.2.4.5.4.1. Market Estimation, 2015 – 2021
11.2.4.5.4.2. Market Forecast, 2022 – 2030
11.2.4.5.5. Latin America
11.2.4.5.5.1. Market Estimation, 2015 – 2021
11.2.4.5.5.2. Market Forecast, 2022 – 2030
11.3. Key Segment for Channeling Investments
11.3.1. By Antitumor Modes of Action for OVs
12. Global Oncolytic Virus Cancer Immunotherapy Market Analysis and Forecasts, 2022 – 2030
12.1. Overview
12.2. Global Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
12.2.1. Intratumoral Dose
12.2.1.1. Definition
12.2.1.2. Market Estimation and Penetration, 2015 – 2021
12.2.1.3. Market Forecast, 2022 – 2030
12.2.1.4. Compound Annual Growth Rate (CAGR)
12.2.1.5. Regional Bifurcation
12.2.1.5.1. North America
12.2.1.5.1.1. Market Estimation, 2015 – 2021
12.2.1.5.1.2. Market Forecast, 2022 – 2030
12.2.1.5.2. Europe
12.2.1.5.2.1. Market Estimation, 2015 – 2021
12.2.1.5.2.2. Market Forecast, 2022 – 2030
12.2.1.5.3. Asia Pacific
12.2.1.5.3.1. Market Estimation, 2015 – 2021
12.2.1.5.3.2. Market Forecast, 2022 – 2030
12.2.1.5.4. Middle East and Africa
12.2.1.5.4.1. Market Estimation, 2015 – 2021
12.2.1.5.4.2. Market Forecast, 2022 – 2030
12.2.1.5.5. Latin America
12.2.1.5.5.1. Market Estimation, 2015 – 2021
12.2.1.5.5.2. Market Forecast, 2022 – 2030
12.2.2. Intravenous
12.2.2.1. Definition
12.2.2.2. Market Estimation and Penetration, 2015 – 2021
12.2.2.3. Market Forecast, 2022 – 2030
12.2.2.4. Compound Annual Growth Rate (CAGR)
12.2.2.5. Regional Bifurcation
12.2.2.5.1. North America
12.2.2.5.1.1. Market Estimation, 2015 – 2021
12.2.2.5.1.2. Market Forecast, 2022 – 2030
12.2.2.5.2. Europe
12.2.2.5.2.1. Market Estimation, 2015 – 2021
12.2.2.5.2.2. Market Forecast, 2022 – 2030
12.2.2.5.3. Asia Pacific
12.2.2.5.3.1. Market Estimation, 2015 – 2021
12.2.2.5.3.2. Market Forecast, 2022 – 2030
12.2.2.5.4. Middle East and Africa
12.2.2.5.4.1. Market Estimation, 2015 – 2021
12.2.2.5.4.2. Market Forecast, 2022 – 2030
12.2.2.5.5. Latin America
12.2.2.5.5.1. Market Estimation, 2015 – 2021
12.2.2.5.5.2. Market Forecast, 2022 – 2030
12.3. Key Segment for Channeling Investments
12.3.1. By Route
13. Global Oncolytic Virus Cancer Immunotherapy Market Analysis and Forecasts, 2022 – 2030
13.1. Overview
13.2. Global Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
13.2.1. Lung Cancer
13.2.1.1. Definition
13.2.1.2. Market Estimation and Penetration, 2015 – 2021
13.2.1.3. Market Forecast, 2022 – 2030
13.2.1.4. Compound Annual Growth Rate (CAGR)
13.2.1.5. Regional Bifurcation
13.2.1.5.1. North America
13.2.1.5.1.1. Market Estimation, 2015 – 2021
13.2.1.5.1.2. Market Forecast, 2022 – 2030
13.2.1.5.2. Europe
13.2.1.5.2.1. Market Estimation, 2015 – 2021
13.2.1.5.2.2. Market Forecast, 2022 – 2030
13.2.1.5.3. Asia Pacific
13.2.1.5.3.1. Market Estimation, 2015 – 2021
13.2.1.5.3.2. Market Forecast, 2022 – 2030
13.2.1.5.4. Middle East and Africa
13.2.1.5.4.1. Market Estimation, 2015 – 2021
13.2.1.5.4.2. Market Forecast, 2022 – 2030
13.2.1.5.5. Latin America
13.2.1.5.5.1. Market Estimation, 2015 – 2021
13.2.1.5.5.2. Market Forecast, 2022 – 2030
13.2.2. Breast Cancer
13.2.2.1. Definition
13.2.2.2. Market Estimation and Penetration, 2015 – 2021
13.2.2.3. Market Forecast, 2022 – 2030
13.2.2.4. Compound Annual Growth Rate (CAGR)
13.2.2.5. Regional Bifurcation
13.2.2.5.1. North America
13.2.2.5.1.1. Market Estimation, 2015 – 2021
13.2.2.5.1.2. Market Forecast, 2022 – 2030
13.2.2.5.2. Europe
13.2.2.5.2.1. Market Estimation, 2015 – 2021
13.2.2.5.2.2. Market Forecast, 2022 – 2030
13.2.2.5.3. Asia Pacific
13.2.2.5.3.1. Market Estimation, 2015 – 2021
13.2.2.5.3.2. Market Forecast, 2022 – 2030
13.2.2.5.4. Middle East and Africa
13.2.2.5.4.1. Market Estimation, 2015 – 2021
13.2.2.5.4.2. Market Forecast, 2022 – 2030
13.2.2.5.5. Latin America
13.2.2.5.5.1. Market Estimation, 2015 – 2021
13.2.2.5.5.2. Market Forecast, 2022 – 2030
13.2.3. Colorectal Cancer
13.2.3.1. Definition
13.2.3.2. Market Estimation and Penetration, 2015 – 2021
13.2.3.3. Market Forecast, 2022 – 2030
13.2.3.4. Compound Annual Growth Rate (CAGR)
13.2.3.5. Regional Bifurcation
13.2.3.5.1. North America
13.2.3.5.1.1. Market Estimation, 2015 – 2021
13.2.3.5.1.2. Market Forecast, 2022 – 2030
13.2.3.5.2. Europe
13.2.3.5.2.1. Market Estimation, 2015 – 2021
13.2.3.5.2.2. Market Forecast, 2022 – 2030
13.2.3.5.3. Asia Pacific
13.2.3.5.3.1. Market Estimation, 2015 – 2021
13.2.3.5.3.2. Market Forecast, 2022 – 2030
13.2.3.5.4. Middle East and Africa
13.2.3.5.4.1. Market Estimation, 2015 – 2021
13.2.3.5.4.2. Market Forecast, 2022 – 2030
13.2.3.5.5. Latin America
13.2.3.5.5.1. Market Estimation, 2015 – 2021
13.2.3.5.5.2. Market Forecast, 2022 – 2030
13.2.4. Melanoma
13.2.4.1. Definition
13.2.4.2. Market Estimation and Penetration, 2015 – 2021
13.2.4.3. Market Forecast, 2022 – 2030
13.2.4.4. Compound Annual Growth Rate (CAGR)
13.2.4.5. Regional Bifurcation
13.2.4.5.1. North America
13.2.4.5.1.1. Market Estimation, 2015 – 2021
13.2.4.5.1.2. Market Forecast, 2022 – 2030
13.2.4.5.2. Europe
13.2.4.5.2.1. Market Estimation, 2015 – 2021
13.2.4.5.2.2. Market Forecast, 2022 – 2030
13.2.4.5.3. Asia Pacific
13.2.4.5.3.1. Market Estimation, 2015 – 2021
13.2.4.5.3.2. Market Forecast, 2022 – 2030
13.2.4.5.4. Middle East and Africa
13.2.4.5.4.1. Market Estimation, 2015 – 2021
13.2.4.5.4.2. Market Forecast, 2022 – 2030
13.2.4.5.5. Latin America
13.2.4.5.5.1. Market Estimation, 2015 – 2021
13.2.4.5.5.2. Market Forecast, 2022 – 2030
13.2.5. Prostate Cancer
13.2.5.1. Definition
13.2.5.2. Market Estimation and Penetration, 2015 – 2021
13.2.5.3. Market Forecast, 2022 – 2030
13.2.5.4. Compound Annual Growth Rate (CAGR)
13.2.5.5. Regional Bifurcation
13.2.5.5.1. North America
13.2.5.5.1.1. Market Estimation, 2015 – 2021
13.2.5.5.1.2. Market Forecast, 2022 – 2030
13.2.5.5.2. Europe
13.2.5.5.2.1. Market Estimation, 2015 – 2021
13.2.5.5.2.2. Market Forecast, 2022 – 2030
13.2.5.5.3. Asia Pacific
13.2.5.5.3.1. Market Estimation, 2015 – 2021
13.2.5.5.3.2. Market Forecast, 2022 – 2030
13.2.5.5.4. Middle East and Africa
13.2.5.5.4.1. Market Estimation, 2015 – 2021
13.2.5.5.4.2. Market Forecast, 2022 – 2030
13.2.5.5.5. Latin America
13.2.5.5.5.1. Market Estimation, 2015 – 2021
13.2.5.5.5.2. Market Forecast, 2022 – 2030
13.2.6. Head and Neck Cancer
13.2.6.1. Definition
13.2.6.2. Market Estimation and Penetration, 2015 – 2021
13.2.6.3. Market Forecast, 2022 – 2030
13.2.6.4. Compound Annual Growth Rate (CAGR)
13.2.6.5. Regional Bifurcation
13.2.6.5.1. North America
13.2.6.5.1.1. Market Estimation, 2015 – 2021
13.2.6.5.1.2. Market Forecast, 2022 – 2030
13.2.6.5.2. Europe
13.2.6.5.2.1. Market Estimation, 2015 – 2021
13.2.6.5.2.2. Market Forecast, 2022 – 2030
13.2.6.5.3. Asia Pacific
13.2.6.5.3.1. Market Estimation, 2015 – 2021
13.2.6.5.3.2. Market Forecast, 2022 – 2030
13.2.6.5.4. Middle East and Africa
13.2.6.5.4.1. Market Estimation, 2015 – 2021
13.2.6.5.4.2. Market Forecast, 2022 – 2030
13.2.6.5.5. Latin America
13.2.6.5.5.1. Market Estimation, 2015 – 2021
13.2.6.5.5.2. Market Forecast, 2022 – 2030
13.2.7. Ovarian Cancer
13.2.7.1. Definition
13.2.7.2. Market Estimation and Penetration, 2015 – 2021
13.2.7.3. Market Forecast, 2022 – 2030
13.2.7.4. Compound Annual Growth Rate (CAGR)
13.2.7.5. Regional Bifurcation
13.2.7.5.1. North America
13.2.7.5.1.1. Market Estimation, 2015 – 2021
13.2.7.5.1.2. Market Forecast, 2022 – 2030
13.2.7.5.2. Europe
13.2.7.5.2.1. Market Estimation, 2015 – 2021
13.2.7.5.2.2. Market Forecast, 2022 – 2030
13.2.7.5.3. Asia Pacific
13.2.7.5.3.1. Market Estimation, 2015 – 2021
13.2.7.5.3.2. Market Forecast, 2022 – 2030
13.2.7.5.4. Middle East and Africa
13.2.7.5.4.1. Market Estimation, 2015 – 2021
13.2.7.5.4.2. Market Forecast, 2022 – 2030
13.2.7.5.5. Latin America
13.2.7.5.5.1. Market Estimation, 2015 – 2021
13.2.7.5.5.2. Market Forecast, 2022 – 2030
13.2.8. Pancreatic Cancer
13.2.8.1. Definition
13.2.8.2. Market Estimation and Penetration, 2015 – 2021
13.2.8.3. Market Forecast, 2022 – 2030
13.2.8.4. Compound Annual Growth Rate (CAGR)
13.2.8.5. Regional Bifurcation
13.2.8.5.1. North America
13.2.8.5.1.1. Market Estimation, 2015 – 2021
13.2.8.5.1.2. Market Forecast, 2022 – 2030
13.2.8.5.2. Europe
13.2.8.5.2.1. Market Estimation, 2015 – 2021
13.2.8.5.2.2. Market Forecast, 2022 – 2030
13.2.8.5.3. Asia Pacific
13.2.8.5.3.1. Market Estimation, 2015 – 2021
13.2.8.5.3.2. Market Forecast, 2022 – 2030
13.2.8.5.4. Middle East and Africa
13.2.8.5.4.1. Market Estimation, 2015 – 2021
13.2.8.5.4.2. Market Forecast, 2022 – 2030
13.2.8.5.5. Latin America
13.2.8.5.5.1. Market Estimation, 2015 – 2021
13.2.8.5.5.2. Market Forecast, 2022 – 2030
13.2.9. Appendiceal Cancer
13.2.9.1. Definition
13.2.9.2. Market Estimation and Penetration, 2015 – 2021
13.2.9.3. Market Forecast, 2022 – 2030
13.2.9.4. Compound Annual Growth Rate (CAGR)
13.2.9.5. Regional Bifurcation
13.2.9.5.1. North America
13.2.9.5.1.1. Market Estimation, 2015 – 2021
13.2.9.5.1.2. Market Forecast, 2022 – 2030
13.2.9.5.2. Europe
13.2.9.5.2.1. Market Estimation, 2015 – 2021
13.2.9.5.2.2. Market Forecast, 2022 – 2030
13.2.9.5.3. Asia Pacific
13.2.9.5.3.1. Market Estimation, 2015 – 2021
13.2.9.5.3.2. Market Forecast, 2022 – 2030
13.2.9.5.4. Middle East and Africa
13.2.9.5.4.1. Market Estimation, 2015 – 2021
13.2.9.5.4.2. Market Forecast, 2022 – 2030
13.2.9.5.5. Latin America
13.2.9.5.5.1. Market Estimation, 2015 – 2021
13.2.9.5.5.2. Market Forecast, 2022 – 2030
13.2.10. Others
13.2.10.1. Definition
13.2.10.2. Market Estimation and Penetration, 2015 – 2021
13.2.10.3. Market Forecast, 2022 – 2030
13.2.10.4. Compound Annual Growth Rate (CAGR)
13.2.10.5. Regional Bifurcation
13.2.10.5.1. North America
13.2.10.5.1.1. Market Estimation, 2015 – 2021
13.2.10.5.1.2. Market Forecast, 2022 – 2030
13.2.10.5.2. Europe
13.2.10.5.2.1. Market Estimation, 2015 – 2021
13.2.10.5.2.2. Market Forecast, 2022 – 2030
13.2.10.5.3. Asia Pacific
13.2.10.5.3.1. Market Estimation, 2015 – 2021
13.2.10.5.3.2. Market Forecast, 2022 – 2030
13.2.10.5.4. Middle East and Africa
13.2.10.5.4.1. Market Estimation, 2015 – 2021
13.2.10.5.4.2. Market Forecast, 2022 – 2030
13.2.10.5.5. Latin America
13.2.10.5.5.1. Market Estimation, 2015 – 2021
13.2.10.5.5.2. Market Forecast, 2022 – 2030
13.3. Key Segment for Channeling Investments
13.3.1. By Cancer Type
14. Global Oncolytic Virus Cancer Immunotherapy Market Analysis and Forecasts, 2022 – 2030
14.1. Overview
14.2. Global Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
14.2.1. Hospitals
14.2.1.1. Definition
14.2.1.2. Market Estimation and Penetration, 2015 – 2021
14.2.1.3. Market Forecast, 2022 – 2030
14.2.1.4. Compound Annual Growth Rate (CAGR)
14.2.1.5. Regional Bifurcation
14.2.1.5.1. North America
14.2.1.5.1.1. Market Estimation, 2015 – 2021
14.2.1.5.1.2. Market Forecast, 2022 – 2030
14.2.1.5.2. Europe
14.2.1.5.2.1. Market Estimation, 2015 – 2021
14.2.1.5.2.2. Market Forecast, 2022 – 2030
14.2.1.5.3. Asia Pacific
14.2.1.5.3.1. Market Estimation, 2015 – 2021
14.2.1.5.3.2. Market Forecast, 2022 – 2030
14.2.1.5.4. Middle East and Africa
14.2.1.5.4.1. Market Estimation, 2015 – 2021
14.2.1.5.4.2. Market Forecast, 2022 – 2030
14.2.1.5.5. Latin America
14.2.1.5.5.1. Market Estimation, 2015 – 2021
14.2.1.5.5.2. Market Forecast, 2022 – 2030
14.2.2. Clinics
14.2.2.1. Definition
14.2.2.2. Market Estimation and Penetration, 2015 – 2021
14.2.2.3. Market Forecast, 2022 – 2030
14.2.2.4. Compound Annual Growth Rate (CAGR)
14.2.2.5. Regional Bifurcation
14.2.2.5.1. North America
14.2.2.5.1.1. Market Estimation, 2015 – 2021
14.2.2.5.1.2. Market Forecast, 2022 – 2030
14.2.2.5.2. Europe
14.2.2.5.2.1. Market Estimation, 2015 – 2021
14.2.2.5.2.2. Market Forecast, 2022 – 2030
14.2.2.5.3. Asia Pacific
14.2.2.5.3.1. Market Estimation, 2015 – 2021
14.2.2.5.3.2. Market Forecast, 2022 – 2030
14.2.2.5.4. Middle East and Africa
14.2.2.5.4.1. Market Estimation, 2015 – 2021
14.2.2.5.4.2. Market Forecast, 2022 – 2030
14.2.2.5.5. Latin America
14.2.2.5.5.1. Market Estimation, 2015 – 2021
14.2.2.5.5.2. Market Forecast, 2022 – 2030
14.2.3. Others
14.2.3.1. Definition
14.2.3.2. Market Estimation and Penetration, 2015 – 2021
14.2.3.3. Market Forecast, 2022 – 2030
14.2.3.4. Compound Annual Growth Rate (CAGR)
14.2.3.5. Regional Bifurcation
14.2.3.5.1. North America
14.2.3.5.1.1. Market Estimation, 2015 – 2021
14.2.3.5.1.2. Market Forecast, 2022 – 2030
14.2.3.5.2. Europe
14.2.3.5.2.1. Market Estimation, 2015 – 2021
14.2.3.5.2.2. Market Forecast, 2022 – 2030
14.2.3.5.3. Asia Pacific
14.2.3.5.3.1. Market Estimation, 2015 – 2021
14.2.3.5.3.2. Market Forecast, 2022 – 2030
14.2.3.5.4. Middle East and Africa
14.2.3.5.4.1. Market Estimation, 2015 – 2021
14.2.3.5.4.2. Market Forecast, 2022 – 2030
14.2.3.5.5. Latin America
14.2.3.5.5.1. Market Estimation, 2015 – 2021
14.2.3.5.5.2. Market Forecast, 2022 – 2030
14.3. Key Segment for Channeling Investments
14.3.1. By End Users
15. North America Oncolytic Virus Cancer Immunotherapy Market Analysis and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. North America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn)
15.2. North America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
15.2.1. Adenovirus
15.2.2. Herpes Simplex Virus
15.2.3. Maraba Virus
15.2.4. Measles
15.2.5. Newcastle Disease Virus
15.2.6. Picornavirus
15.2.7. Reovirus
15.2.8. Vaccinia Virus
15.2.9. Vesicular Stomatitis Virus
15.2.10. Coxsackie Virus
15.2.11. Others
15.3. North America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
15.3.1. Phase 0
15.3.2. Phase I
15.3.3. Phase II
15.3.4. Phase III
15.3.5. Phase IV
15.4. North America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
15.4.1. Immune Checkpoint Inhibitors
15.4.2. T-cell Transfer Therapy
15.4.3. Monoclonal Antibodies
15.4.4. Treatment Vaccines
15.4.5. Immune System Modulators
15.4.6. Combination Types
15.5. North America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
15.5.1. Oncolysis
15.5.2. Transgene Expression
15.5.3. Vascular Collapse
15.5.4. Antitumor Immunity
15.6. North America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
15.6.1. Intratumoral Dose
15.6.2. Intravenous
15.7. North America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
15.7.1. Lung Cancer
15.7.2. Breast Cancer
15.7.3. Colorectal Cancer
15.7.4. Melanoma
15.7.5. Prostate Cancer
15.7.6. Head and Neck Cancer
15.7.7. Ovarian Cancer
15.7.8. Pancreatic Cancer
15.7.9. Appendiceal Cancer
15.7.10. Others
15.8. North America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
15.8.1. Hospitals
15.8.2. Clinics
15.8.3. Others
15.9. North America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Country
15.9.1. U.S
15.9.1.1. U.S Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
15.9.1.1.1. Adenovirus
15.9.1.1.2. Herpes Simplex Virus
15.9.1.1.3. Maraba Virus
15.9.1.1.4. Measles
15.9.1.1.5. Newcastle Disease Virus
15.9.1.1.6. Picornavirus
15.9.1.1.7. Reovirus
15.9.1.1.8. Vaccinia Virus
15.9.1.1.9. Vesicular Stomatitis Virus
15.9.1.1.10. Coxsackie Virus
15.9.1.1.11. Others
15.9.1.2. U.S Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
15.9.1.2.1. Phase 0
15.9.1.2.2. Phase I
15.9.1.2.3. Phase II
15.9.1.2.4. Phase III
15.9.1.2.5. Phase IV
15.9.1.3. U.S Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
15.9.1.3.1. Immune Checkpoint Inhibitors
15.9.1.3.2. T-cell Transfer Therapy
15.9.1.3.3. Monoclonal Antibodies
15.9.1.3.4. Treatment Vaccines
15.9.1.3.5. Immune System Modulators
15.9.1.3.6. Combination Types
15.9.1.4. U.S Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
15.9.1.4.1. Oncolysis
15.9.1.4.2. Transgene Expression
15.9.1.4.3. Vascular Collapse
15.9.1.4.4. Antitumor Immunity
15.9.1.5. U.S Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
15.9.1.5.1. Intratumoral Dose
15.9.1.5.2. Intravenous
15.9.1.6. U.S Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
15.9.1.6.1. Lung Cancer
15.9.1.6.2. Breast Cancer
15.9.1.6.3. Colorectal Cancer
15.9.1.6.4. Melanoma
15.9.1.6.5. Prostate Cancer
15.9.1.6.6. Head and Neck Cancer
15.9.1.6.7. Ovarian Cancer
15.9.1.6.8. Pancreatic Cancer
15.9.1.6.9. Appendiceal Cancer
15.9.1.6.10. Others
15.9.1.7. U.S Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
15.9.1.7.1. Hospitals
15.9.1.7.2. Clinics
15.9.1.7.3. Others
15.9.2. Canada
15.9.2.1. Canada Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
15.9.2.1.1. Adenovirus
15.9.2.1.2. Herpes Simplex Virus
15.9.2.1.3. Maraba Virus
15.9.2.1.4. Measles
15.9.2.1.5. Newcastle Disease Virus
15.9.2.1.6. Picornavirus
15.9.2.1.7. Reovirus
15.9.2.1.8. Vaccinia Virus
15.9.2.1.9. Vesicular Stomatitis Virus
15.9.2.1.10. Coxsackie Virus
15.9.2.1.11. Others
15.9.2.2. Canada Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
15.9.2.2.1. Phase 0
15.9.2.2.2. Phase I
15.9.2.2.3. Phase II
15.9.2.2.4. Phase III
15.9.2.2.5. Phase IV
15.9.2.3. Canada Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
15.9.2.3.1. Immune Checkpoint Inhibitors
15.9.2.3.2. T-cell Transfer Therapy
15.9.2.3.3. Monoclonal Antibodies
15.9.2.3.4. Treatment Vaccines
15.9.2.3.5. Immune System Modulators
15.9.2.3.6. Combination Types
15.9.2.4. Canada Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
15.9.2.4.1. Oncolysis
15.9.2.4.2. Transgene Expression
15.9.2.4.3. Vascular Collapse
15.9.2.4.4. Antitumor Immunity
15.9.2.5. Canada Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
15.9.2.5.1. Intratumoral Dose
15.9.2.5.2. Intravenous
15.9.2.6. Canada Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
15.9.2.6.1. Lung Cancer
15.9.2.6.2. Breast Cancer
15.9.2.6.3. Colorectal Cancer
15.9.2.6.4. Melanoma
15.9.2.6.5. Prostate Cancer
15.9.2.6.6. Head and Neck Cancer
15.9.2.6.7. Ovarian Cancer
15.9.2.6.8. Pancreatic Cancer
15.9.2.6.9. Appendiceal Cancer
15.9.2.6.10. Others
15.9.2.7. Canada Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
15.9.2.7.1. Hospitals
15.9.2.7.2. Clinics
15.9.2.7.3. Others
15.9.3. Mexico
15.9.3.1. Mexico Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
15.9.3.1.1. Adenovirus
15.9.3.1.2. Herpes Simplex Virus
15.9.3.1.3. Maraba Virus
15.9.3.1.4. Measles
15.9.3.1.5. Newcastle Disease Virus
15.9.3.1.6. Picornavirus
15.9.3.1.7. Reovirus
15.9.3.1.8. Vaccinia Virus
15.9.3.1.9. Vesicular Stomatitis Virus
15.9.3.1.10. Coxsackie Virus
15.9.3.1.11. Others
15.9.3.2. Mexico Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
15.9.3.2.1. Phase 0
15.9.3.2.2. Phase I
15.9.3.2.3. Phase II
15.9.3.2.4. Phase III
15.9.3.2.5. Phase IV
15.9.3.3. Mexico Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
15.9.3.3.1. Immune Checkpoint Inhibitors
15.9.3.3.2. T-cell Transfer Therapy
15.9.3.3.3. Monoclonal Antibodies
15.9.3.3.4. Treatment Vaccines
15.9.3.3.5. Immune System Modulators
15.9.3.3.6. Combination Types
15.9.3.4. Mexico Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
15.9.3.4.1. Oncolysis
15.9.3.4.2. Transgene Expression
15.9.3.4.3. Vascular Collapse
15.9.3.4.4. Antitumor Immunity
15.9.3.5. Mexico Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
15.9.3.5.1. Intratumoral Dose
15.9.3.5.2. Intravenous
15.9.3.6. Mexico Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
15.9.3.6.1. Lung Cancer
15.9.3.6.2. Breast Cancer
15.9.3.6.3. Colorectal Cancer
15.9.3.6.4. Melanoma
15.9.3.6.5. Prostate Cancer
15.9.3.6.6. Head and Neck Cancer
15.9.3.6.7. Ovarian Cancer
15.9.3.6.8. Pancreatic Cancer
15.9.3.6.9. Appendiceal Cancer
15.9.3.6.10. Others
15.9.3.7. Mexico Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
15.9.3.7.1. Hospitals
15.9.3.7.2. Clinics
15.9.3.7.3. Others
15.9.4. Rest of North America
15.9.4.1. Rest of North America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
15.9.4.1.1. Adenovirus
15.9.4.1.2. Herpes Simplex Virus
15.9.4.1.3. Maraba Virus
15.9.4.1.4. Measles
15.9.4.1.5. Newcastle Disease Virus
15.9.4.1.6. Picornavirus
15.9.4.1.7. Reovirus
15.9.4.1.8. Vaccinia Virus
15.9.4.1.9. Vesicular Stomatitis Virus
15.9.4.1.10. Coxsackie Virus
15.9.4.1.11. Others
15.9.4.2. Rest of North America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
15.9.4.2.1. Phase 0
15.9.4.2.2. Phase I
15.9.4.2.3. Phase II
15.9.4.2.4. Phase III
15.9.4.2.5. Phase IV
15.9.4.3. Rest of North America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
15.9.4.3.1. Immune Checkpoint Inhibitors
15.9.4.3.2. T-cell Transfer Therapy
15.9.4.3.3. Monoclonal Antibodies
15.9.4.3.4. Treatment Vaccines
15.9.4.3.5. Immune System Modulators
15.9.4.3.6. Combination Types
15.9.4.4. Rest of North America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
15.9.4.4.1. Oncolysis
15.9.4.4.2. Transgene Expression
15.9.4.4.3. Vascular Collapse
15.9.4.4.4. Antitumor Immunity
15.9.4.5. Rest of North America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
15.9.4.5.1. Intratumoral Dose
15.9.4.5.2. Intravenous
15.9.4.6. Rest of North America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
15.9.4.6.1. Lung Cancer
15.9.4.6.2. Breast Cancer
15.9.4.6.3. Colorectal Cancer
15.9.4.6.4. Melanoma
15.9.4.6.5. Prostate Cancer
15.9.4.6.6. Head and Neck Cancer
15.9.4.6.7. Ovarian Cancer
15.9.4.6.8. Pancreatic Cancer
15.9.4.6.9. Appendiceal Cancer
15.9.4.6.10. Others
15.9.4.7. Rest of North America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
15.9.4.7.1. Hospitals
15.9.4.7.2. Clinics
15.9.4.7.3. Others
15.10. Key Segment for Channeling Investments
15.10.1. By Country
15.10.2. By Virus Type
15.10.3. By Clinical Trial Phases
15.10.4. By Immunotherapy Type
15.10.5. By Antitumor Modes of Action for OVs
15.10.6. By Route
15.10.7. By Cancer Type
15.10.8. By End Users
16. Europe Oncolytic Virus Cancer Immunotherapy Market Analysis and Forecasts, 2022 - 2030
16.1. Overview
16.1.1. Europe Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn)
16.2. Europe Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
16.2.1. Adenovirus
16.2.2. Herpes Simplex Virus
16.2.3. Maraba Virus
16.2.4. Measles
16.2.5. Newcastle Disease Virus
16.2.6. Picornavirus
16.2.7. Reovirus
16.2.8. Vaccinia Virus
16.2.9. Vesicular Stomatitis Virus
16.2.10. Coxsackie Virus
16.2.11. Others
16.3. Europe Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
16.3.1. Phase 0
16.3.2. Phase I
16.3.3. Phase II
16.3.4. Phase III
16.3.5. Phase IV
16.4. Europe Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
16.4.1. Immune Checkpoint Inhibitors
16.4.2. T-cell Transfer Therapy
16.4.3. Monoclonal Antibodies
16.4.4. Treatment Vaccines
16.4.5. Immune System Modulators
16.4.6. Combination Types
16.5. Europe Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
16.5.1. Oncolysis
16.5.2. Transgene Expression
16.5.3. Vascular Collapse
16.5.4. Antitumor Immunity
16.6. Europe Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
16.6.1. Intratumoral Dose
16.6.2. Intravenous
16.7. Europe Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
16.7.1. Lung Cancer
16.7.2. Breast Cancer
16.7.3. Colorectal Cancer
16.7.4. Melanoma
16.7.5. Prostate Cancer
16.7.6. Head and Neck Cancer
16.7.7. Ovarian Cancer
16.7.8. Pancreatic Cancer
16.7.9. Appendiceal Cancer
16.7.10. Others
16.8. Europe Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
16.8.1. Hospitals
16.8.2. Clinics
16.8.3. Others
16.9. Europe Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Country
16.9.1. France
16.9.1.1. France Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
16.9.1.1.1. Adenovirus
16.9.1.1.2. Herpes Simplex Virus
16.9.1.1.3. Maraba Virus
16.9.1.1.4. Measles
16.9.1.1.5. Newcastle Disease Virus
16.9.1.1.6. Picornavirus
16.9.1.1.7. Reovirus
16.9.1.1.8. Vaccinia Virus
16.9.1.1.9. Vesicular Stomatitis Virus
16.9.1.1.10. Coxsackie Virus
16.9.1.1.11. Others
16.9.1.2. France Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
16.9.1.2.1. Phase 0
16.9.1.2.2. Phase I
16.9.1.2.3. Phase II
16.9.1.2.4. Phase III
16.9.1.2.5. Phase IV
16.9.1.3. France Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
16.9.1.3.1. Immune Checkpoint Inhibitors
16.9.1.3.2. T-cell Transfer Therapy
16.9.1.3.3. Monoclonal Antibodies
16.9.1.3.4. Treatment Vaccines
16.9.1.3.5. Immune System Modulators
16.9.1.3.6. Combination Types
16.9.1.4. France Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
16.9.1.4.1. Oncolysis
16.9.1.4.2. Transgene Expression
16.9.1.4.3. Vascular Collapse
16.9.1.4.4. Antitumor Immunity
16.9.1.5. France Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
16.9.1.5.1. Intratumoral Dose
16.9.1.5.2. Intravenous
16.9.1.6. France Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
16.9.1.6.1. Lung Cancer
16.9.1.6.2. Breast Cancer
16.9.1.6.3. Colorectal Cancer
16.9.1.6.4. Melanoma
16.9.1.6.5. Prostate Cancer
16.9.1.6.6. Head and Neck Cancer
16.9.1.6.7. Ovarian Cancer
16.9.1.6.8. Pancreatic Cancer
16.9.1.6.9. Appendiceal Cancer
16.9.1.6.10. Others
16.9.1.7. France Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
16.9.1.7.1. Hospitals
16.9.1.7.2. Clinics
16.9.1.7.3. Others
16.9.2. The UK
16.9.2.1. The UK Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
16.9.2.1.1. Adenovirus
16.9.2.1.2. Herpes Simplex Virus
16.9.2.1.3. Maraba Virus
16.9.2.1.4. Measles
16.9.2.1.5. Newcastle Disease Virus
16.9.2.1.6. Picornavirus
16.9.2.1.7. Reovirus
16.9.2.1.8. Vaccinia Virus
16.9.2.1.9. Vesicular Stomatitis Virus
16.9.2.1.10. Coxsackie Virus
16.9.2.1.11. Others
16.9.2.2. The UK Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
16.9.2.2.1. Phase 0
16.9.2.2.2. Phase I
16.9.2.2.3. Phase II
16.9.2.2.4. Phase III
16.9.2.2.5. Phase IV
16.9.2.3. The UK Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
16.9.2.3.1. Immune Checkpoint Inhibitors
16.9.2.3.2. T-cell Transfer Therapy
16.9.2.3.3. Monoclonal Antibodies
16.9.2.3.4. Treatment Vaccines
16.9.2.3.5. Immune System Modulators
16.9.2.3.6. Combination Types
16.9.2.4. The UK Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
16.9.2.4.1. Oncolysis
16.9.2.4.2. Transgene Expression
16.9.2.4.3. Vascular Collapse
16.9.2.4.4. Antitumor Immunity
16.9.2.5. The UK Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
16.9.2.5.1. Intratumoral Dose
16.9.2.5.2. Intravenous
16.9.2.6. The UK Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
16.9.2.6.1. Lung Cancer
16.9.2.6.2. Breast Cancer
16.9.2.6.3. Colorectal Cancer
16.9.2.6.4. Melanoma
16.9.2.6.5. Prostate Cancer
16.9.2.6.6. Head and Neck Cancer
16.9.2.6.7. Ovarian Cancer
16.9.2.6.8. Pancreatic Cancer
16.9.2.6.9. Appendiceal Cancer
16.9.2.6.10. Others
16.9.2.7. The UK Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
16.9.2.7.1. Hospitals
16.9.2.7.2. Clinics
16.9.2.7.3. Others
16.9.3. Spain
16.9.3.1. Spain Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
16.9.3.1.1. Adenovirus
16.9.3.1.2. Herpes Simplex Virus
16.9.3.1.3. Maraba Virus
16.9.3.1.4. Measles
16.9.3.1.5. Newcastle Disease Virus
16.9.3.1.6. Picornavirus
16.9.3.1.7. Reovirus
16.9.3.1.8. Vaccinia Virus
16.9.3.1.9. Vesicular Stomatitis Virus
16.9.3.1.10. Coxsackie Virus
16.9.3.1.11. Others
16.9.3.2. Spain Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
16.9.3.2.1. Phase 0
16.9.3.2.2. Phase I
16.9.3.2.3. Phase II
16.9.3.2.4. Phase III
16.9.3.2.5. Phase IV
16.9.3.3. Spain Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
16.9.3.3.1. Immune Checkpoint Inhibitors
16.9.3.3.2. T-cell Transfer Therapy
16.9.3.3.3. Monoclonal Antibodies
16.9.3.3.4. Treatment Vaccines
16.9.3.3.5. Immune System Modulators
16.9.3.3.6. Combination Types
16.9.3.4. Spain Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
16.9.3.4.1. Oncolysis
16.9.3.4.2. Transgene Expression
16.9.3.4.3. Vascular Collapse
16.9.3.4.4. Antitumor Immunity
16.9.3.5. Spain Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
16.9.3.5.1. Intratumoral Dose
16.9.3.5.2. Intravenous
16.9.3.6. Spain Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
16.9.3.6.1. Lung Cancer
16.9.3.6.2. Breast Cancer
16.9.3.6.3. Colorectal Cancer
16.9.3.6.4. Melanoma
16.9.3.6.5. Prostate Cancer
16.9.3.6.6. Head and Neck Cancer
16.9.3.6.7. Ovarian Cancer
16.9.3.6.8. Pancreatic Cancer
16.9.3.6.9. Appendiceal Cancer
16.9.3.6.10. Others
16.9.3.7. Spain Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
16.9.3.7.1. Hospitals
16.9.3.7.2. Clinics
16.9.3.7.3. Others
16.9.4. Germany
16.9.4.1. Germany Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
16.9.4.1.1. Adenovirus
16.9.4.1.2. Herpes Simplex Virus
16.9.4.1.3. Maraba Virus
16.9.4.1.4. Measles
16.9.4.1.5. Newcastle Disease Virus
16.9.4.1.6. Picornavirus
16.9.4.1.7. Reovirus
16.9.4.1.8. Vaccinia Virus
16.9.4.1.9. Vesicular Stomatitis Virus
16.9.4.1.10. Coxsackie Virus
16.9.4.1.11. Others
16.9.4.2. Germany Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
16.9.4.2.1. Phase 0
16.9.4.2.2. Phase I
16.9.4.2.3. Phase II
16.9.4.2.4. Phase III
16.9.4.2.5. Phase IV
16.9.4.3. Germany Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
16.9.4.3.1. Immune Checkpoint Inhibitors
16.9.4.3.2. T-cell Transfer Therapy
16.9.4.3.3. Monoclonal Antibodies
16.9.4.3.4. Treatment Vaccines
16.9.4.3.5. Immune System Modulators
16.9.4.3.6. Combination Types
16.9.4.4. Germany Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
16.9.4.4.1. Oncolysis
16.9.4.4.2. Transgene Expression
16.9.4.4.3. Vascular Collapse
16.9.4.4.4. Antitumor Immunity
16.9.4.5. Germany Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
16.9.4.5.1. Intratumoral Dose
16.9.4.5.2. Intravenous
16.9.4.6. Germany Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
16.9.4.6.1. Lung Cancer
16.9.4.6.2. Breast Cancer
16.9.4.6.3. Colorectal Cancer
16.9.4.6.4. Melanoma
16.9.4.6.5. Prostate Cancer
16.9.4.6.6. Head and Neck Cancer
16.9.4.6.7. Ovarian Cancer
16.9.4.6.8. Pancreatic Cancer
16.9.4.6.9. Appendiceal Cancer
16.9.4.6.10. Others
16.9.4.7. Germany Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
16.9.4.7.1. Hospitals
16.9.4.7.2. Clinics
16.9.4.7.3. Others
16.9.5. Italy
16.9.5.1. Italy Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
16.9.5.1.1. Adenovirus
16.9.5.1.2. Herpes Simplex Virus
16.9.5.1.3. Maraba Virus
16.9.5.1.4. Measles
16.9.5.1.5. Newcastle Disease Virus
16.9.5.1.6. Picornavirus
16.9.5.1.7. Reovirus
16.9.5.1.8. Vaccinia Virus
16.9.5.1.9. Vesicular Stomatitis Virus
16.9.5.1.10. Coxsackie Virus
16.9.5.1.11. Others
16.9.5.2. Italy Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
16.9.5.2.1. Phase 0
16.9.5.2.2. Phase I
16.9.5.2.3. Phase II
16.9.5.2.4. Phase III
16.9.5.2.5. Phase IV
16.9.5.3. Italy Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
16.9.5.3.1. Immune Checkpoint Inhibitors
16.9.5.3.2. T-cell Transfer Therapy
16.9.5.3.3. Monoclonal Antibodies
16.9.5.3.4. Treatment Vaccines
16.9.5.3.5. Immune System Modulators
16.9.5.3.6. Combination Types
16.9.5.4. Italy Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
16.9.5.4.1. Oncolysis
16.9.5.4.2. Transgene Expression
16.9.5.4.3. Vascular Collapse
16.9.5.4.4. Antitumor Immunity
16.9.5.5. Italy Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
16.9.5.5.1. Intratumoral Dose
16.9.5.5.2. Intravenous
16.9.5.6. Italy Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
16.9.5.6.1. Lung Cancer
16.9.5.6.2. Breast Cancer
16.9.5.6.3. Colorectal Cancer
16.9.5.6.4. Melanoma
16.9.5.6.5. Prostate Cancer
16.9.5.6.6. Head and Neck Cancer
16.9.5.6.7. Ovarian Cancer
16.9.5.6.8. Pancreatic Cancer
16.9.5.6.9. Appendiceal Cancer
16.9.5.6.10. Others
16.9.5.7. Italy Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
16.9.5.7.1. Hospitals
16.9.5.7.2. Clinics
16.9.5.7.3. Others
16.9.6. Nordic Countries
16.9.6.1. Nordic Countries Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
16.9.6.1.1. Adenovirus
16.9.6.1.2. Herpes Simplex Virus
16.9.6.1.3. Maraba Virus
16.9.6.1.4. Measles
16.9.6.1.5. Newcastle Disease Virus
16.9.6.1.6. Picornavirus
16.9.6.1.7. Reovirus
16.9.6.1.8. Vaccinia Virus
16.9.6.1.9. Vesicular Stomatitis Virus
16.9.6.1.10. Coxsackie Virus
16.9.6.1.11. Others
16.9.6.2. Nordic Countries Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
16.9.6.2.1. Phase 0
16.9.6.2.2. Phase I
16.9.6.2.3. Phase II
16.9.6.2.4. Phase III
16.9.6.2.5. Phase IV
16.9.6.3. Nordic Countries Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
16.9.6.3.1. Immune Checkpoint Inhibitors
16.9.6.3.2. T-cell Transfer Therapy
16.9.6.3.3. Monoclonal Antibodies
16.9.6.3.4. Treatment Vaccines
16.9.6.3.5. Immune System Modulators
16.9.6.3.6. Combination Types
16.9.6.4. Nordic Countries Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
16.9.6.4.1. Oncolysis
16.9.6.4.2. Transgene Expression
16.9.6.4.3. Vascular Collapse
16.9.6.4.4. Antitumor Immunity
16.9.6.5. Nordic Countries Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
16.9.6.5.1. Intratumoral Dose
16.9.6.5.2. Intravenous
16.9.6.6. Nordic Countries Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
16.9.6.6.1. Lung Cancer
16.9.6.6.2. Breast Cancer
16.9.6.6.3. Colorectal Cancer
16.9.6.6.4. Melanoma
16.9.6.6.5. Prostate Cancer
16.9.6.6.6. Head and Neck Cancer
16.9.6.6.7. Ovarian Cancer
16.9.6.6.8. Pancreatic Cancer
16.9.6.6.9. Appendiceal Cancer
16.9.6.6.10. Others
16.9.6.7. Nordic Countries Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
16.9.6.7.1. Hospitals
16.9.6.7.2. Clinics
16.9.6.7.3. Others
16.9.6.8. Nordic Countries Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Country
16.9.6.8.1. Denmark
16.9.6.8.2. Finland
16.9.6.8.3. Iceland
16.9.6.8.4. Sweden
16.9.6.8.5. Norway
16.9.7. Benelux Union
16.9.7.1. Benelux Union Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
16.9.7.1.1. Adenovirus
16.9.7.1.2. Herpes Simplex Virus
16.9.7.1.3. Maraba Virus
16.9.7.1.4. Measles
16.9.7.1.5. Newcastle Disease Virus
16.9.7.1.6. Picornavirus
16.9.7.1.7. Reovirus
16.9.7.1.8. Vaccinia Virus
16.9.7.1.9. Vesicular Stomatitis Virus
16.9.7.1.10. Coxsackie Virus
16.9.7.1.11. Others
16.9.7.2. Benelux Union Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
16.9.7.2.1. Phase 0
16.9.7.2.2. Phase I
16.9.7.2.3. Phase II
16.9.7.2.4. Phase III
16.9.7.2.5. Phase IV
16.9.7.3. Benelux Union Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
16.9.7.3.1. Immune Checkpoint Inhibitors
16.9.7.3.2. T-cell Transfer Therapy
16.9.7.3.3. Monoclonal Antibodies
16.9.7.3.4. Treatment Vaccines
16.9.7.3.5. Immune System Modulators
16.9.7.3.6. Combination Types
16.9.7.4. Benelux Union Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
16.9.7.4.1. Oncolysis
16.9.7.4.2. Transgene Expression
16.9.7.4.3. Vascular Collapse
16.9.7.4.4. Antitumor Immunity
16.9.7.5. Benelux Union Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
16.9.7.5.1. Intratumoral Dose
16.9.7.5.2. Intravenous
16.9.7.6. Benelux Union Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
16.9.7.6.1. Lung Cancer
16.9.7.6.2. Breast Cancer
16.9.7.6.3. Colorectal Cancer
16.9.7.6.4. Melanoma
16.9.7.6.5. Prostate Cancer
16.9.7.6.6. Head and Neck Cancer
16.9.7.6.7. Ovarian Cancer
16.9.7.6.8. Pancreatic Cancer
16.9.7.6.9. Appendiceal Cancer
16.9.7.6.10. Others
16.9.7.7. Benelux Union Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
16.9.7.7.1. Hospitals
16.9.7.7.2. Clinics
16.9.7.7.3. Others
16.9.7.8. Benelux Union Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Country
16.9.7.8.1. Belgium
16.9.7.8.2. The Netherlands
16.9.7.8.3. Luxembourg
16.9.8. Rest of Europe
16.9.8.1. Rest of Europe Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
16.9.8.1.1. Adenovirus
16.9.8.1.2. Herpes Simplex Virus
16.9.8.1.3. Maraba Virus
16.9.8.1.4. Measles
16.9.8.1.5. Newcastle Disease Virus
16.9.8.1.6. Picornavirus
16.9.8.1.7. Reovirus
16.9.8.1.8. Vaccinia Virus
16.9.8.1.9. Vesicular Stomatitis Virus
16.9.8.1.10. Coxsackie Virus
16.9.8.1.11. Others
16.9.8.2. Rest of Europe Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
16.9.8.2.1. Phase 0
16.9.8.2.2. Phase I
16.9.8.2.3. Phase II
16.9.8.2.4. Phase III
16.9.8.2.5. Phase IV
16.9.8.3. Rest of Europe Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
16.9.8.3.1. Immune Checkpoint Inhibitors
16.9.8.3.2. T-cell Transfer Therapy
16.9.8.3.3. Monoclonal Antibodies
16.9.8.3.4. Treatment Vaccines
16.9.8.3.5. Immune System Modulators
16.9.8.3.6. Combination Types
16.9.8.4. Rest of Europe Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
16.9.8.4.1. Oncolysis
16.9.8.4.2. Transgene Expression
16.9.8.4.3. Vascular Collapse
16.9.8.4.4. Antitumor Immunity
16.9.8.5. Rest of Europe Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
16.9.8.5.1. Intratumoral Dose
16.9.8.5.2. Intravenous
16.9.8.6. Rest of Europe Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
16.9.8.6.1. Lung Cancer
16.9.8.6.2. Breast Cancer
16.9.8.6.3. Colorectal Cancer
16.9.8.6.4. Melanoma
16.9.8.6.5. Prostate Cancer
16.9.8.6.6. Head and Neck Cancer
16.9.8.6.7. Ovarian Cancer
16.9.8.6.8. Pancreatic Cancer
16.9.8.6.9. Appendiceal Cancer
16.9.8.6.10. Others
16.9.8.7. Rest of Europe Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
16.9.8.7.1. Hospitals
16.9.8.7.2. Clinics
16.9.8.7.3. Others
16.10. Key Segment for Channeling Investments
16.10.1. By Country
16.10.2. By Virus Type
16.10.3. By Clinical Trial Phases
16.10.4. By Immunotherapy Type
16.10.5. By Antitumor Modes of Action for OVs
16.10.6. By Route
16.10.7. By Cancer Type
16.10.8. By End Users
17. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Analysis and Forecasts, 2022 - 2030
17.1. Overview
17.1.1. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn)
17.2. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
17.2.1. Adenovirus
17.2.2. Herpes Simplex Virus
17.2.3. Maraba Virus
17.2.4. Measles
17.2.5. Newcastle Disease Virus
17.2.6. Picornavirus
17.2.7. Reovirus
17.2.8. Vaccinia Virus
17.2.9. Vesicular Stomatitis Virus
17.2.10. Coxsackie Virus
17.2.11. Others
17.3. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
17.3.1. Phase 0
17.3.2. Phase I
17.3.3. Phase II
17.3.4. Phase III
17.3.5. Phase IV
17.4. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
17.4.1. Immune Checkpoint Inhibitors
17.4.2. T-cell Transfer Therapy
17.4.3. Monoclonal Antibodies
17.4.4. Treatment Vaccines
17.4.5. Immune System Modulators
17.4.6. Combination Types
17.5. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
17.5.1. Oncolysis
17.5.2. Transgene Expression
17.5.3. Vascular Collapse
17.5.4. Antitumor Immunity
17.6. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
17.6.1. Intratumoral Dose
17.6.2. Intravenous
17.7. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
17.7.1. Lung Cancer
17.7.2. Breast Cancer
17.7.3. Colorectal Cancer
17.7.4. Melanoma
17.7.5. Prostate Cancer
17.7.6. Head and Neck Cancer
17.7.7. Ovarian Cancer
17.7.8. Pancreatic Cancer
17.7.9. Appendiceal Cancer
17.7.10. Others
17.8. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
17.8.1. Hospitals
17.8.2. Clinics
17.8.3. Others
17.9. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Country
17.9.1. China
17.9.1.1. China Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
17.9.1.1.1. Adenovirus
17.9.1.1.2. Herpes Simplex Virus
17.9.1.1.3. Maraba Virus
17.9.1.1.4. Measles
17.9.1.1.5. Newcastle Disease Virus
17.9.1.1.6. Picornavirus
17.9.1.1.7. Reovirus
17.9.1.1.8. Vaccinia Virus
17.9.1.1.9. Vesicular Stomatitis Virus
17.9.1.1.10. Coxsackie Virus
17.9.1.1.11. Others
17.9.1.2. China Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
17.9.1.2.1. Phase 0
17.9.1.2.2. Phase I
17.9.1.2.3. Phase II
17.9.1.2.4. Phase III
17.9.1.2.5. Phase IV
17.9.1.3. China Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
17.9.1.3.1. Immune Checkpoint Inhibitors
17.9.1.3.2. T-cell Transfer Therapy
17.9.1.3.3. Monoclonal Antibodies
17.9.1.3.4. Treatment Vaccines
17.9.1.3.5. Immune System Modulators
17.9.1.3.6. Combination Types
17.9.1.4. China Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
17.9.1.4.1. Oncolysis
17.9.1.4.2. Transgene Expression
17.9.1.4.3. Vascular Collapse
17.9.1.4.4. Antitumor Immunity
17.9.1.5. China Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
17.9.1.5.1. Intratumoral Dose
17.9.1.5.2. Intravenous
17.9.1.6. China Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
17.9.1.6.1. Lung Cancer
17.9.1.6.2. Breast Cancer
17.9.1.6.3. Colorectal Cancer
17.9.1.6.4. Melanoma
17.9.1.6.5. Prostate Cancer
17.9.1.6.6. Head and Neck Cancer
17.9.1.6.7. Ovarian Cancer
17.9.1.6.8. Pancreatic Cancer
17.9.1.6.9. Appendiceal Cancer
17.9.1.6.10. Others
17.9.1.7. China Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
17.9.1.7.1. Hospitals
17.9.1.7.2. Clinics
17.9.1.7.3. Others
17.9.2. Japan
17.9.2.1. Japan Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
17.9.2.1.1. Adenovirus
17.9.2.1.2. Herpes Simplex Virus
17.9.2.1.3. Maraba Virus
17.9.2.1.4. Measles
17.9.2.1.5. Newcastle Disease Virus
17.9.2.1.6. Picornavirus
17.9.2.1.7. Reovirus
17.9.2.1.8. Vaccinia Virus
17.9.2.1.9. Vesicular Stomatitis Virus
17.9.2.1.10. Coxsackie Virus
17.9.2.1.11. Others
17.9.2.2. Japan Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
17.9.2.2.1. Phase 0
17.9.2.2.2. Phase I
17.9.2.2.3. Phase II
17.9.2.2.4. Phase III
17.9.2.2.5. Phase IV
17.9.2.3. Japan Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
17.9.2.3.1. Immune Checkpoint Inhibitors
17.9.2.3.2. T-cell Transfer Therapy
17.9.2.3.3. Monoclonal Antibodies
17.9.2.3.4. Treatment Vaccines
17.9.2.3.5. Immune System Modulators
17.9.2.3.6. Combination Types
17.9.2.4. Japan Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
17.9.2.4.1. Oncolysis
17.9.2.4.2. Transgene Expression
17.9.2.4.3. Vascular Collapse
17.9.2.4.4. Antitumor Immunity
17.9.2.5. Japan Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
17.9.2.5.1. Intratumoral Dose
17.9.2.5.2. Intravenous
17.9.2.6. Japan Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
17.9.2.6.1. Lung Cancer
17.9.2.6.2. Breast Cancer
17.9.2.6.3. Colorectal Cancer
17.9.2.6.4. Melanoma
17.9.2.6.5. Prostate Cancer
17.9.2.6.6. Head and Neck Cancer
17.9.2.6.7. Ovarian Cancer
17.9.2.6.8. Pancreatic Cancer
17.9.2.6.9. Appendiceal Cancer
17.9.2.6.10. Others
17.9.2.7. Japan Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
17.9.2.7.1. Hospitals
17.9.2.7.2. Clinics
17.9.2.7.3. Others
17.9.3. India
17.9.3.1. India Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
17.9.3.1.1. Adenovirus
17.9.3.1.2. Herpes Simplex Virus
17.9.3.1.3. Maraba Virus
17.9.3.1.4. Measles
17.9.3.1.5. Newcastle Disease Virus
17.9.3.1.6. Picornavirus
17.9.3.1.7. Reovirus
17.9.3.1.8. Vaccinia Virus
17.9.3.1.9. Vesicular Stomatitis Virus
17.9.3.1.10. Coxsackie Virus
17.9.3.1.11. Others
17.9.3.2. India Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
17.9.3.2.1. Phase 0
17.9.3.2.2. Phase I
17.9.3.2.3. Phase II
17.9.3.2.4. Phase III
17.9.3.2.5. Phase IV
17.9.3.3. India Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
17.9.3.3.1. Immune Checkpoint Inhibitors
17.9.3.3.2. T-cell Transfer Therapy
17.9.3.3.3. Monoclonal Antibodies
17.9.3.3.4. Treatment Vaccines
17.9.3.3.5. Immune System Modulators
17.9.3.3.6. Combination Types
17.9.3.4. India Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
17.9.3.4.1. Oncolysis
17.9.3.4.2. Transgene Expression
17.9.3.4.3. Vascular Collapse
17.9.3.4.4. Antitumor Immunity
17.9.3.5. India Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
17.9.3.5.1. Intratumoral Dose
17.9.3.5.2. Intravenous
17.9.3.6. India Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
17.9.3.6.1. Lung Cancer
17.9.3.6.2. Breast Cancer
17.9.3.6.3. Colorectal Cancer
17.9.3.6.4. Melanoma
17.9.3.6.5. Prostate Cancer
17.9.3.6.6. Head and Neck Cancer
17.9.3.6.7. Ovarian Cancer
17.9.3.6.8. Pancreatic Cancer
17.9.3.6.9. Appendiceal Cancer
17.9.3.6.10. Others
17.9.3.7. India Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
17.9.3.7.1. Hospitals
17.9.3.7.2. Clinics
17.9.3.7.3. Others
17.9.4. New Zealand
17.9.4.1. New Zealand Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
17.9.4.1.1. Adenovirus
17.9.4.1.2. Herpes Simplex Virus
17.9.4.1.3. Maraba Virus
17.9.4.1.4. Measles
17.9.4.1.5. Newcastle Disease Virus
17.9.4.1.6. Picornavirus
17.9.4.1.7. Reovirus
17.9.4.1.8. Vaccinia Virus
17.9.4.1.9. Vesicular Stomatitis Virus
17.9.4.1.10. Coxsackie Virus
17.9.4.1.11. Others
17.9.4.2. New Zealand Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
17.9.4.2.1. Phase 0
17.9.4.2.2. Phase I
17.9.4.2.3. Phase II
17.9.4.2.4. Phase III
17.9.4.2.5. Phase IV
17.9.4.3. New Zealand Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
17.9.4.3.1. Immune Checkpoint Inhibitors
17.9.4.3.2. T-cell Transfer Therapy
17.9.4.3.3. Monoclonal Antibodies
17.9.4.3.4. Treatment Vaccines
17.9.4.3.5. Immune System Modulators
17.9.4.3.6. Combination Types
17.9.4.4. New Zealand Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
17.9.4.4.1. Oncolysis
17.9.4.4.2. Transgene Expression
17.9.4.4.3. Vascular Collapse
17.9.4.4.4. Antitumor Immunity
17.9.4.5. New Zealand Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
17.9.4.5.1. Intratumoral Dose
17.9.4.5.2. Intravenous
17.9.4.6. New Zealand Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
17.9.4.6.1. Lung Cancer
17.9.4.6.2. Breast Cancer
17.9.4.6.3. Colorectal Cancer
17.9.4.6.4. Melanoma
17.9.4.6.5. Prostate Cancer
17.9.4.6.6. Head and Neck Cancer
17.9.4.6.7. Ovarian Cancer
17.9.4.6.8. Pancreatic Cancer
17.9.4.6.9. Appendiceal Cancer
17.9.4.6.10. Others
17.9.4.7. New Zealand Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
17.9.4.7.1. Hospitals
17.9.4.7.2. Clinics
17.9.4.7.3. Others
17.9.5. Australia
17.9.5.1. Australia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
17.9.5.1.1. Adenovirus
17.9.5.1.2. Herpes Simplex Virus
17.9.5.1.3. Maraba Virus
17.9.5.1.4. Measles
17.9.5.1.5. Newcastle Disease Virus
17.9.5.1.6. Picornavirus
17.9.5.1.7. Reovirus
17.9.5.1.8. Vaccinia Virus
17.9.5.1.9. Vesicular Stomatitis Virus
17.9.5.1.10. Coxsackie Virus
17.9.5.1.11. Others
17.9.5.2. Australia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
17.9.5.2.1. Phase 0
17.9.5.2.2. Phase I
17.9.5.2.3. Phase II
17.9.5.2.4. Phase III
17.9.5.2.5. Phase IV
17.9.5.3. Australia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
17.9.5.3.1. Immune Checkpoint Inhibitors
17.9.5.3.2. T-cell Transfer Therapy
17.9.5.3.3. Monoclonal Antibodies
17.9.5.3.4. Treatment Vaccines
17.9.5.3.5. Immune System Modulators
17.9.5.3.6. Combination Types
17.9.5.4. Australia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
17.9.5.4.1. Oncolysis
17.9.5.4.2. Transgene Expression
17.9.5.4.3. Vascular Collapse
17.9.5.4.4. Antitumor Immunity
17.9.5.5. Australia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
17.9.5.5.1. Intratumoral Dose
17.9.5.5.2. Intravenous
17.9.5.6. Australia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
17.9.5.6.1. Lung Cancer
17.9.5.6.2. Breast Cancer
17.9.5.6.3. Colorectal Cancer
17.9.5.6.4. Melanoma
17.9.5.6.5. Prostate Cancer
17.9.5.6.6. Head and Neck Cancer
17.9.5.6.7. Ovarian Cancer
17.9.5.6.8. Pancreatic Cancer
17.9.5.6.9. Appendiceal Cancer
17.9.5.6.10. Others
17.9.5.7. Australia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
17.9.5.7.1. Hospitals
17.9.5.7.2. Clinics
17.9.5.7.3. Others
17.9.6. South Korea
17.9.6.1. South Korea Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
17.9.6.1.1. Adenovirus
17.9.6.1.2. Herpes Simplex Virus
17.9.6.1.3. Maraba Virus
17.9.6.1.4. Measles
17.9.6.1.5. Newcastle Disease Virus
17.9.6.1.6. Picornavirus
17.9.6.1.7. Reovirus
17.9.6.1.8. Vaccinia Virus
17.9.6.1.9. Vesicular Stomatitis Virus
17.9.6.1.10. Coxsackie Virus
17.9.6.1.11. Others
17.9.6.2. South Korea Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
17.9.6.2.1. Phase 0
17.9.6.2.2. Phase I
17.9.6.2.3. Phase II
17.9.6.2.4. Phase III
17.9.6.2.5. Phase IV
17.9.6.3. South Korea Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
17.9.6.3.1. Immune Checkpoint Inhibitors
17.9.6.3.2. T-cell Transfer Therapy
17.9.6.3.3. Monoclonal Antibodies
17.9.6.3.4. Treatment Vaccines
17.9.6.3.5. Immune System Modulators
17.9.6.3.6. Combination Types
17.9.6.4. South Korea Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
17.9.6.4.1. Oncolysis
17.9.6.4.2. Transgene Expression
17.9.6.4.3. Vascular Collapse
17.9.6.4.4. Antitumor Immunity
17.9.6.5. South Korea Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
17.9.6.5.1. Intratumoral Dose
17.9.6.5.2. Intravenous
17.9.6.6. South Korea Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
17.9.6.6.1. Lung Cancer
17.9.6.6.2. Breast Cancer
17.9.6.6.3. Colorectal Cancer
17.9.6.6.4. Melanoma
17.9.6.6.5. Prostate Cancer
17.9.6.6.6. Head and Neck Cancer
17.9.6.6.7. Ovarian Cancer
17.9.6.6.8. Pancreatic Cancer
17.9.6.6.9. Appendiceal Cancer
17.9.6.6.10. Others
17.9.6.7. South Korea Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
17.9.6.7.1. Hospitals
17.9.6.7.2. Clinics
17.9.6.7.3. Others
17.9.7. Southeast Asia
17.9.7.1. Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
17.9.7.1.1. Adenovirus
17.9.7.1.2. Herpes Simplex Virus
17.9.7.1.3. Maraba Virus
17.9.7.1.4. Measles
17.9.7.1.5. Newcastle Disease Virus
17.9.7.1.6. Picornavirus
17.9.7.1.7. Reovirus
17.9.7.1.8. Vaccinia Virus
17.9.7.1.9. Vesicular Stomatitis Virus
17.9.7.1.10. Coxsackie Virus
17.9.7.1.11. Others
17.9.7.2. Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
17.9.7.2.1. Phase 0
17.9.7.2.2. Phase I
17.9.7.2.3. Phase II
17.9.7.2.4. Phase III
17.9.7.2.5. Phase IV
17.9.7.3. Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
17.9.7.3.1. Immune Checkpoint Inhibitors
17.9.7.3.2. T-cell Transfer Therapy
17.9.7.3.3. Monoclonal Antibodies
17.9.7.3.4. Treatment Vaccines
17.9.7.3.5. Immune System Modulators
17.9.7.3.6. Combination Types
17.9.7.4. Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
17.9.7.4.1. Oncolysis
17.9.7.4.2. Transgene Expression
17.9.7.4.3. Vascular Collapse
17.9.7.4.4. Antitumor Immunity
17.9.7.5. Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
17.9.7.5.1. Intratumoral Dose
17.9.7.5.2. Intravenous
17.9.7.6. Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
17.9.7.6.1. Lung Cancer
17.9.7.6.2. Breast Cancer
17.9.7.6.3. Colorectal Cancer
17.9.7.6.4. Melanoma
17.9.7.6.5. Prostate Cancer
17.9.7.6.6. Head and Neck Cancer
17.9.7.6.7. Ovarian Cancer
17.9.7.6.8. Pancreatic Cancer
17.9.7.6.9. Appendiceal Cancer
17.9.7.6.10. Others
17.9.7.7. Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
17.9.7.7.1. Hospitals
17.9.7.7.2. Clinics
17.9.7.7.3. Others
17.9.7.8. Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Country
17.9.7.8.1. Indonesia
17.9.7.8.2. Thailand
17.9.7.8.3. Malaysia
17.9.7.8.4. Singapore
17.9.7.8.5. Rest of Southeast Asia
17.9.8. Rest of Asia Pacific
17.9.8.1. Rest of Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
17.9.8.1.1. Adenovirus
17.9.8.1.2. Herpes Simplex Virus
17.9.8.1.3. Maraba Virus
17.9.8.1.4. Measles
17.9.8.1.5. Newcastle Disease Virus
17.9.8.1.6. Picornavirus
17.9.8.1.7. Reovirus
17.9.8.1.8. Vaccinia Virus
17.9.8.1.9. Vesicular Stomatitis Virus
17.9.8.1.10. Coxsackie Virus
17.9.8.1.11. Others
17.9.8.2. Rest of Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
17.9.8.2.1. Phase 0
17.9.8.2.2. Phase I
17.9.8.2.3. Phase II
17.9.8.2.4. Phase III
17.9.8.2.5. Phase IV
17.9.8.3. Rest of Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
17.9.8.3.1. Immune Checkpoint Inhibitors
17.9.8.3.2. T-cell Transfer Therapy
17.9.8.3.3. Monoclonal Antibodies
17.9.8.3.4. Treatment Vaccines
17.9.8.3.5. Immune System Modulators
17.9.8.3.6. Combination Types
17.9.8.4. Rest of Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
17.9.8.4.1. Oncolysis
17.9.8.4.2. Transgene Expression
17.9.8.4.3. Vascular Collapse
17.9.8.4.4. Antitumor Immunity
17.9.8.5. Rest of Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
17.9.8.5.1. Intratumoral Dose
17.9.8.5.2. Intravenous
17.9.8.6. Rest of Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
17.9.8.6.1. Lung Cancer
17.9.8.6.2. Breast Cancer
17.9.8.6.3. Colorectal Cancer
17.9.8.6.4. Melanoma
17.9.8.6.5. Prostate Cancer
17.9.8.6.6. Head and Neck Cancer
17.9.8.6.7. Ovarian Cancer
17.9.8.6.8. Pancreatic Cancer
17.9.8.6.9. Appendiceal Cancer
17.9.8.6.10. Others
17.9.8.7. Rest of Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
17.9.8.7.1. Hospitals
17.9.8.7.2. Clinics
17.9.8.7.3. Others
17.10. Key Segment for Channeling Investments
17.10.1. By Country
17.10.2. By Virus Type
17.10.3. By Clinical Trial Phases
17.10.4. By Immunotherapy Type
17.10.5. By Antitumor Modes of Action for OVs
17.10.6. By Route
17.10.7. By Cancer Type
17.10.8. By End Users
18. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Analysis and Forecasts, 2022 - 2030
18.1. Overview
18.1.1. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn)
18.2. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
18.2.1. Adenovirus
18.2.2. Herpes Simplex Virus
18.2.3. Maraba Virus
18.2.4. Measles
18.2.5. Newcastle Disease Virus
18.2.6. Picornavirus
18.2.7. Reovirus
18.2.8. Vaccinia Virus
18.2.9. Vesicular Stomatitis Virus
18.2.10. Coxsackie Virus
18.2.11. Others
18.3. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
18.3.1. Phase 0
18.3.2. Phase I
18.3.3. Phase II
18.3.4. Phase III
18.3.5. Phase IV
18.4. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
18.4.1. Immune Checkpoint Inhibitors
18.4.2. T-cell Transfer Therapy
18.4.3. Monoclonal Antibodies
18.4.4. Treatment Vaccines
18.4.5. Immune System Modulators
18.4.6. Combination Types
18.5. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
18.5.1. Oncolysis
18.5.2. Transgene Expression
18.5.3. Vascular Collapse
18.5.4. Antitumor Immunity
18.6. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
18.6.1. Intratumoral Dose
18.6.2. Intravenous
18.7. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
18.7.1. Lung Cancer
18.7.2. Breast Cancer
18.7.3. Colorectal Cancer
18.7.4. Melanoma
18.7.5. Prostate Cancer
18.7.6. Head and Neck Cancer
18.7.7. Ovarian Cancer
18.7.8. Pancreatic Cancer
18.7.9. Appendiceal Cancer
18.7.10. Others
18.8. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
18.8.1. Hospitals
18.8.2. Clinics
18.8.3. Others
18.9. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Country
18.9.1. Saudi Arabia
18.9.1.1. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
18.9.1.1.1. Adenovirus
18.9.1.1.2. Herpes Simplex Virus
18.9.1.1.3. Maraba Virus
18.9.1.1.4. Measles
18.9.1.1.5. Newcastle Disease Virus
18.9.1.1.6. Picornavirus
18.9.1.1.7. Reovirus
18.9.1.1.8. Vaccinia Virus
18.9.1.1.9. Vesicular Stomatitis Virus
18.9.1.1.10. Coxsackie Virus
18.9.1.1.11. Others
18.9.1.2. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
18.9.1.2.1. Phase 0
18.9.1.2.2. Phase I
18.9.1.2.3. Phase II
18.9.1.2.4. Phase III
18.9.1.2.5. Phase IV
18.9.1.3. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
18.9.1.3.1. Immune Checkpoint Inhibitors
18.9.1.3.2. T-cell Transfer Therapy
18.9.1.3.3. Monoclonal Antibodies
18.9.1.3.4. Treatment Vaccines
18.9.1.3.5. Immune System Modulators
18.9.1.3.6. Combination Types
18.9.1.4. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
18.9.1.4.1. Oncolysis
18.9.1.4.2. Transgene Expression
18.9.1.4.3. Vascular Collapse
18.9.1.4.4. Antitumor Immunity
18.9.1.5. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
18.9.1.5.1. Intratumoral Dose
18.9.1.5.2. Intravenous
18.9.1.6. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
18.9.1.6.1. Lung Cancer
18.9.1.6.2. Breast Cancer
18.9.1.6.3. Colorectal Cancer
18.9.1.6.4. Melanoma
18.9.1.6.5. Prostate Cancer
18.9.1.6.6. Head and Neck Cancer
18.9.1.6.7. Ovarian Cancer
18.9.1.6.8. Pancreatic Cancer
18.9.1.6.9. Appendiceal Cancer
18.9.1.6.10. Others
18.9.1.7. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
18.9.1.7.1. Hospitals
18.9.1.7.2. Clinics
18.9.1.7.3. Others
18.9.2. UAE
18.9.2.1. UAE Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
18.9.2.1.1. Adenovirus
18.9.2.1.2. Herpes Simplex Virus
18.9.2.1.3. Maraba Virus
18.9.2.1.4. Measles
18.9.2.1.5. Newcastle Disease Virus
18.9.2.1.6. Picornavirus
18.9.2.1.7. Reovirus
18.9.2.1.8. Vaccinia Virus
18.9.2.1.9. Vesicular Stomatitis Virus
18.9.2.1.10. Coxsackie Virus
18.9.2.1.11. Others
18.9.2.2. UAE Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
18.9.2.2.1. Phase 0
18.9.2.2.2. Phase I
18.9.2.2.3. Phase II
18.9.2.2.4. Phase III
18.9.2.2.5. Phase IV
18.9.2.3. UAE Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
18.9.2.3.1. Immune Checkpoint Inhibitors
18.9.2.3.2. T-cell Transfer Therapy
18.9.2.3.3. Monoclonal Antibodies
18.9.2.3.4. Treatment Vaccines
18.9.2.3.5. Immune System Modulators
18.9.2.3.6. Combination Types
18.9.2.4. UAE Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
18.9.2.4.1. Oncolysis
18.9.2.4.2. Transgene Expression
18.9.2.4.3. Vascular Collapse
18.9.2.4.4. Antitumor Immunity
18.9.2.5. UAE Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
18.9.2.5.1. Intratumoral Dose
18.9.2.5.2. Intravenous
18.9.2.6. UAE Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
18.9.2.6.1. Lung Cancer
18.9.2.6.2. Breast Cancer
18.9.2.6.3. Colorectal Cancer
18.9.2.6.4. Melanoma
18.9.2.6.5. Prostate Cancer
18.9.2.6.6. Head and Neck Cancer
18.9.2.6.7. Ovarian Cancer
18.9.2.6.8. Pancreatic Cancer
18.9.2.6.9. Appendiceal Cancer
18.9.2.6.10. Others
18.9.2.7. UAE Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
18.9.2.7.1. Hospitals
18.9.2.7.2. Clinics
18.9.2.7.3. Others
18.9.3. Egypt
18.9.3.1. Egypt Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
18.9.3.1.1. Adenovirus
18.9.3.1.2. Herpes Simplex Virus
18.9.3.1.3. Maraba Virus
18.9.3.1.4. Measles
18.9.3.1.5. Newcastle Disease Virus
18.9.3.1.6. Picornavirus
18.9.3.1.7. Reovirus
18.9.3.1.8. Vaccinia Virus
18.9.3.1.9. Vesicular Stomatitis Virus
18.9.3.1.10. Coxsackie Virus
18.9.3.1.11. Others
18.9.3.2. Egypt Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
18.9.3.2.1. Phase 0
18.9.3.2.2. Phase I
18.9.3.2.3. Phase II
18.9.3.2.4. Phase III
18.9.3.2.5. Phase IV
18.9.3.3. Egypt Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
18.9.3.3.1. Immune Checkpoint Inhibitors
18.9.3.3.2. T-cell Transfer Therapy
18.9.3.3.3. Monoclonal Antibodies
18.9.3.3.4. Treatment Vaccines
18.9.3.3.5. Immune System Modulators
18.9.3.3.6. Combination Types
18.9.3.4. Egypt Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
18.9.3.4.1. Oncolysis
18.9.3.4.2. Transgene Expression
18.9.3.4.3. Vascular Collapse
18.9.3.4.4. Antitumor Immunity
18.9.3.5. Egypt Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
18.9.3.5.1. Intratumoral Dose
18.9.3.5.2. Intravenous
18.9.3.6. Egypt Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
18.9.3.6.1. Lung Cancer
18.9.3.6.2. Breast Cancer
18.9.3.6.3. Colorectal Cancer
18.9.3.6.4. Melanoma
18.9.3.6.5. Prostate Cancer
18.9.3.6.6. Head and Neck Cancer
18.9.3.6.7. Ovarian Cancer
18.9.3.6.8. Pancreatic Cancer
18.9.3.6.9. Appendiceal Cancer
18.9.3.6.10. Others
18.9.3.7. Egypt Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
18.9.3.7.1. Hospitals
18.9.3.7.2. Clinics
18.9.3.7.3. Others
18.9.4. Kuwait
18.9.4.1. Kuwait Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
18.9.4.1.1. Adenovirus
18.9.4.1.2. Herpes Simplex Virus
18.9.4.1.3. Maraba Virus
18.9.4.1.4. Measles
18.9.4.1.5. Newcastle Disease Virus
18.9.4.1.6. Picornavirus
18.9.4.1.7. Reovirus
18.9.4.1.8. Vaccinia Virus
18.9.4.1.9. Vesicular Stomatitis Virus
18.9.4.1.10. Coxsackie Virus
18.9.4.1.11. Others
18.9.4.2. Kuwait Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
18.9.4.2.1. Phase 0
18.9.4.2.2. Phase I
18.9.4.2.3. Phase II
18.9.4.2.4. Phase III
18.9.4.2.5. Phase IV
18.9.4.3. Kuwait Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
18.9.4.3.1. Immune Checkpoint Inhibitors
18.9.4.3.2. T-cell Transfer Therapy
18.9.4.3.3. Monoclonal Antibodies
18.9.4.3.4. Treatment Vaccines
18.9.4.3.5. Immune System Modulators
18.9.4.3.6. Combination Types
18.9.4.4. Kuwait Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
18.9.4.4.1. Oncolysis
18.9.4.4.2. Transgene Expression
18.9.4.4.3. Vascular Collapse
18.9.4.4.4. Antitumor Immunity
18.9.4.5. Kuwait Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
18.9.4.5.1. Intratumoral Dose
18.9.4.5.2. Intravenous
18.9.4.6. Kuwait Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
18.9.4.6.1. Lung Cancer
18.9.4.6.2. Breast Cancer
18.9.4.6.3. Colorectal Cancer
18.9.4.6.4. Melanoma
18.9.4.6.5. Prostate Cancer
18.9.4.6.6. Head and Neck Cancer
18.9.4.6.7. Ovarian Cancer
18.9.4.6.8. Pancreatic Cancer
18.9.4.6.9. Appendiceal Cancer
18.9.4.6.10. Others
18.9.4.7. Kuwait Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
18.9.4.7.1. Hospitals
18.9.4.7.2. Clinics
18.9.4.7.3. Others
18.9.5. South Africa
18.9.5.1. South Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
18.9.5.1.1. Adenovirus
18.9.5.1.2. Herpes Simplex Virus
18.9.5.1.3. Maraba Virus
18.9.5.1.4. Measles
18.9.5.1.5. Newcastle Disease Virus
18.9.5.1.6. Picornavirus
18.9.5.1.7. Reovirus
18.9.5.1.8. Vaccinia Virus
18.9.5.1.9. Vesicular Stomatitis Virus
18.9.5.1.10. Coxsackie Virus
18.9.5.1.11. Others
18.9.5.2. South Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
18.9.5.2.1. Phase 0
18.9.5.2.2. Phase I
18.9.5.2.3. Phase II
18.9.5.2.4. Phase III
18.9.5.2.5. Phase IV
18.9.5.3. South Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
18.9.5.3.1. Immune Checkpoint Inhibitors
18.9.5.3.2. T-cell Transfer Therapy
18.9.5.3.3. Monoclonal Antibodies
18.9.5.3.4. Treatment Vaccines
18.9.5.3.5. Immune System Modulators
18.9.5.3.6. Combination Types
18.9.5.4. South Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
18.9.5.4.1. Oncolysis
18.9.5.4.2. Transgene Expression
18.9.5.4.3. Vascular Collapse
18.9.5.4.4. Antitumor Immunity
18.9.5.5. South Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
18.9.5.5.1. Intratumoral Dose
18.9.5.5.2. Intravenous
18.9.5.6. South Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
18.9.5.6.1. Lung Cancer
18.9.5.6.2. Breast Cancer
18.9.5.6.3. Colorectal Cancer
18.9.5.6.4. Melanoma
18.9.5.6.5. Prostate Cancer
18.9.5.6.6. Head and Neck Cancer
18.9.5.6.7. Ovarian Cancer
18.9.5.6.8. Pancreatic Cancer
18.9.5.6.9. Appendiceal Cancer
18.9.5.6.10. Others
18.9.5.7. South Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
18.9.5.7.1. Hospitals
18.9.5.7.2. Clinics
18.9.5.7.3. Others
18.9.6. Rest of Middle East & Africa
18.9.6.1. Rest of Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
18.9.6.1.1. Adenovirus
18.9.6.1.2. Herpes Simplex Virus
18.9.6.1.3. Maraba Virus
18.9.6.1.4. Measles
18.9.6.1.5. Newcastle Disease Virus
18.9.6.1.6. Picornavirus
18.9.6.1.7. Reovirus
18.9.6.1.8. Vaccinia Virus
18.9.6.1.9. Vesicular Stomatitis Virus
18.9.6.1.10. Coxsackie Virus
18.9.6.1.11. Others
18.9.6.2. Rest of Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
18.9.6.2.1. Phase 0
18.9.6.2.2. Phase I
18.9.6.2.3. Phase II
18.9.6.2.4. Phase III
18.9.6.2.5. Phase IV
18.9.6.3. Rest of Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
18.9.6.3.1. Immune Checkpoint Inhibitors
18.9.6.3.2. T-cell Transfer Therapy
18.9.6.3.3. Monoclonal Antibodies
18.9.6.3.4. Treatment Vaccines
18.9.6.3.5. Immune System Modulators
18.9.6.3.6. Combination Types
18.9.6.4. Rest of Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
18.9.6.4.1. Oncolysis
18.9.6.4.2. Transgene Expression
18.9.6.4.3. Vascular Collapse
18.9.6.4.4. Antitumor Immunity
18.9.6.5. Rest of Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
18.9.6.5.1. Intratumoral Dose
18.9.6.5.2. Intravenous
18.9.6.6. Rest of Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
18.9.6.6.1. Lung Cancer
18.9.6.6.2. Breast Cancer
18.9.6.6.3. Colorectal Cancer
18.9.6.6.4. Melanoma
18.9.6.6.5. Prostate Cancer
18.9.6.6.6. Head and Neck Cancer
18.9.6.6.7. Ovarian Cancer
18.9.6.6.8. Pancreatic Cancer
18.9.6.6.9. Appendiceal Cancer
18.9.6.6.10. Others
18.9.6.7. Rest of Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
18.9.6.7.1. Hospitals
18.9.6.7.2. Clinics
18.9.6.7.3. Others
18.10. Key Segment for Channeling Investments
18.10.1. By Country
18.10.2. By Virus Type
18.10.3. By Clinical Trial Phases
18.10.4. By Immunotherapy Type
18.10.5. By Antitumor Modes of Action for OVs
18.10.6. By Route
18.10.7. By Cancer Type
18.10.8. By End Users
19. Latin America Oncolytic Virus Cancer Immunotherapy Market Analysis and Forecasts, 2022 - 2030
19.1. Overview
19.1.1. Latin America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn)
19.2. Latin America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
19.2.1. Adenovirus
19.2.2. Herpes Simplex Virus
19.2.3. Maraba Virus
19.2.4. Measles
19.2.5. Newcastle Disease Virus
19.2.6. Picornavirus
19.2.7. Reovirus
19.2.8. Vaccinia Virus
19.2.9. Vesicular Stomatitis Virus
19.2.10. Coxsackie Virus
19.2.11. Others
19.3. Latin America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
19.3.1. Phase 0
19.3.2. Phase I
19.3.3. Phase II
19.3.4. Phase III
19.3.5. Phase IV
19.4. Latin America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
19.4.1. Immune Checkpoint Inhibitors
19.4.2. T-cell Transfer Therapy
19.4.3. Monoclonal Antibodies
19.4.4. Treatment Vaccines
19.4.5. Immune System Modulators
19.4.6. Combination Types
19.5. Latin America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
19.5.1. Oncolysis
19.5.2. Transgene Expression
19.5.3. Vascular Collapse
19.5.4. Antitumor Immunity
19.6. Latin America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
19.6.1. Intratumoral Dose
19.6.2. Intravenous
19.7. Latin America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
19.7.1. Lung Cancer
19.7.2. Breast Cancer
19.7.3. Colorectal Cancer
19.7.4. Melanoma
19.7.5. Prostate Cancer
19.7.6. Head and Neck Cancer
19.7.7. Ovarian Cancer
19.7.8. Pancreatic Cancer
19.7.9. Appendiceal Cancer
19.7.10. Others
19.8. Latin America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
19.8.1. Hospitals
19.8.2. Clinics
19.8.3. Others
19.9. Latin America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Country
19.9.1. Brazil
19.9.1.1. Brazil Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
19.9.1.1.1. Adenovirus
19.9.1.1.2. Herpes Simplex Virus
19.9.1.1.3. Maraba Virus
19.9.1.1.4. Measles
19.9.1.1.5. Newcastle Disease Virus
19.9.1.1.6. Picornavirus
19.9.1.1.7. Reovirus
19.9.1.1.8. Vaccinia Virus
19.9.1.1.9. Vesicular Stomatitis Virus
19.9.1.1.10. Coxsackie Virus
19.9.1.1.11. Others
19.9.1.2. Brazil Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
19.9.1.2.1. Phase 0
19.9.1.2.2. Phase I
19.9.1.2.3. Phase II
19.9.1.2.4. Phase III
19.9.1.2.5. Phase IV
19.9.1.3. Brazil Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
19.9.1.3.1. Immune Checkpoint Inhibitors
19.9.1.3.2. T-cell Transfer Therapy
19.9.1.3.3. Monoclonal Antibodies
19.9.1.3.4. Treatment Vaccines
19.9.1.3.5. Immune System Modulators
19.9.1.3.6. Combination Types
19.9.1.4. Brazil Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
19.9.1.4.1. Oncolysis
19.9.1.4.2. Transgene Expression
19.9.1.4.3. Vascular Collapse
19.9.1.4.4. Antitumor Immunity
19.9.1.5. Brazil Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
19.9.1.5.1. Intratumoral Dose
19.9.1.5.2. Intravenous
19.9.1.6. Brazil Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
19.9.1.6.1. Lung Cancer
19.9.1.6.2. Breast Cancer
19.9.1.6.3. Colorectal Cancer
19.9.1.6.4. Melanoma
19.9.1.6.5. Prostate Cancer
19.9.1.6.6. Head and Neck Cancer
19.9.1.6.7. Ovarian Cancer
19.9.1.6.8. Pancreatic Cancer
19.9.1.6.9. Appendiceal Cancer
19.9.1.6.10. Others
19.9.1.7. Brazil Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
19.9.1.7.1. Hospitals
19.9.1.7.2. Clinics
19.9.1.7.3. Others
19.9.2. Argentina
19.9.2.1. Argentina Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
19.9.2.1.1. Adenovirus
19.9.2.1.2. Herpes Simplex Virus
19.9.2.1.3. Maraba Virus
19.9.2.1.4. Measles
19.9.2.1.5. Newcastle Disease Virus
19.9.2.1.6. Picornavirus
19.9.2.1.7. Reovirus
19.9.2.1.8. Vaccinia Virus
19.9.2.1.9. Vesicular Stomatitis Virus
19.9.2.1.10. Coxsackie Virus
19.9.2.1.11. Others
19.9.2.2. Argentina Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
19.9.2.2.1. Phase 0
19.9.2.2.2. Phase I
19.9.2.2.3. Phase II
19.9.2.2.4. Phase III
19.9.2.2.5. Phase IV
19.9.2.3. Argentina Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
19.9.2.3.1. Immune Checkpoint Inhibitors
19.9.2.3.2. T-cell Transfer Therapy
19.9.2.3.3. Monoclonal Antibodies
19.9.2.3.4. Treatment Vaccines
19.9.2.3.5. Immune System Modulators
19.9.2.3.6. Combination Types
19.9.2.4. Argentina Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
19.9.2.4.1. Oncolysis
19.9.2.4.2. Transgene Expression
19.9.2.4.3. Vascular Collapse
19.9.2.4.4. Antitumor Immunity
19.9.2.5. Argentina Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
19.9.2.5.1. Intratumoral Dose
19.9.2.5.2. Intravenous
19.9.2.6. Argentina Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
19.9.2.6.1. Lung Cancer
19.9.2.6.2. Breast Cancer
19.9.2.6.3. Colorectal Cancer
19.9.2.6.4. Melanoma
19.9.2.6.5. Prostate Cancer
19.9.2.6.6. Head and Neck Cancer
19.9.2.6.7. Ovarian Cancer
19.9.2.6.8. Pancreatic Cancer
19.9.2.6.9. Appendiceal Cancer
19.9.2.6.10. Others
19.9.2.7. Argentina Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
19.9.2.7.1. Hospitals
19.9.2.7.2. Clinics
19.9.2.7.3. Others
19.9.3. Rest of Latin America
19.9.3.1. Rest of Latin America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Virus Type
19.9.3.1.1. Adenovirus
19.9.3.1.2. Herpes Simplex Virus
19.9.3.1.3. Maraba Virus
19.9.3.1.4. Measles
19.9.3.1.5. Newcastle Disease Virus
19.9.3.1.6. Picornavirus
19.9.3.1.7. Reovirus
19.9.3.1.8. Vaccinia Virus
19.9.3.1.9. Vesicular Stomatitis Virus
19.9.3.1.10. Coxsackie Virus
19.9.3.1.11. Others
19.9.3.2. Rest of Latin America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phases
19.9.3.2.1. Phase 0
19.9.3.2.2. Phase I
19.9.3.2.3. Phase II
19.9.3.2.4. Phase III
19.9.3.2.5. Phase IV
19.9.3.3. Rest of Latin America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Immunotherapy Type
19.9.3.3.1. Immune Checkpoint Inhibitors
19.9.3.3.2. T-cell Transfer Therapy
19.9.3.3.3. Monoclonal Antibodies
19.9.3.3.4. Treatment Vaccines
19.9.3.3.5. Immune System Modulators
19.9.3.3.6. Combination Types
19.9.3.4. Rest of Latin America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Antitumor Modes of Action for OVs
19.9.3.4.1. Oncolysis
19.9.3.4.2. Transgene Expression
19.9.3.4.3. Vascular Collapse
19.9.3.4.4. Antitumor Immunity
19.9.3.5. Rest of Latin America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Route
19.9.3.5.1. Intratumoral Dose
19.9.3.5.2. Intravenous
19.9.3.6. Rest of Latin America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By Cancer Type
19.9.3.6.1. Lung Cancer
19.9.3.6.2. Breast Cancer
19.9.3.6.3. Colorectal Cancer
19.9.3.6.4. Melanoma
19.9.3.6.5. Prostate Cancer
19.9.3.6.6. Head and Neck Cancer
19.9.3.6.7. Ovarian Cancer
19.9.3.6.8. Pancreatic Cancer
19.9.3.6.9. Appendiceal Cancer
19.9.3.6.10. Others
19.9.3.7. Rest of Latin America Oncolytic Virus Cancer Immunotherapy Market Revenue (US$ Mn) and Forecasts, By End Users
19.9.3.7.1. Hospitals
19.9.3.7.2. Clinics
19.9.3.7.3. Others
19.10. Key Segment for Channeling Investments
19.10.1. By Country
19.10.2. By Virus Type
19.10.3. By Clinical Trial Phases
19.10.4. By Immunotherapy Type
19.10.5. By Antitumor Modes of Action for OVs
19.10.6. By Route
19.10.7. By Cancer Type
19.10.8. By End Users
20. Competitive Benchmarking
20.1. Market Share Analysis, 2021
20.2. Global Presence and Growth Strategies
20.2.1. Mergers and Acquisitions
20.2.2. Product Launches
20.2.3. Investments Trends
20.2.4. R&D Initiatives
21. Player Profiles
21.1. Amgen Inc.
21.1.1. Company Details
21.1.2. Company Overview
21.1.3. Product Offerings
21.1.4. Key Developments
21.1.5. Financial Analysis
21.1.6. SWOT Analysis
21.1.7. Business Strategies
21.2. Astra Zeneca
21.2.1. Company Details
21.2.2. Company Overview
21.2.3. Product Offerings
21.2.4. Key Developments
21.2.5. Financial Analysis
21.2.6. SWOT Analysis
21.2.7. Business Strategies
21.3. Bristol-Myers Squibb Company (in partnership with PsiOxus Therapeutics, Ltd.)
21.3.1. Company Details
21.3.2. Company Overview
21.3.3. Product Offerings
21.3.4. Key Developments
21.3.5. Financial Analysis
21.3.6. SWOT Analysis
21.3.7. Business Strategies
21.4. Daiichi Sankyo Company
21.4.1. Company Details
21.4.2. Company Overview
21.4.3. Product Offerings
21.4.4. Key Developments
21.4.5. Financial Analysis
21.4.6. SWOT Analysis
21.4.7. Business Strategies
21.5. Genelux Corporation
21.5.1. Company Details
21.5.2. Company Overview
21.5.3. Product Offerings
21.5.4. Key Developments
21.5.5. Financial Analysis
21.5.6. SWOT Analysis
21.5.7. Business Strategies
21.6. Lokon Pharma AB
21.6.1. Company Details
21.6.2. Company Overview
21.6.3. Product Offerings
21.6.4. Key Developments
21.6.5. Financial Analysis
21.6.6. SWOT Analysis
21.6.7. Business Strategies
21.7. Merck & Co. (Viralytics)
21.7.1. Company Details
21.7.2. Company Overview
21.7.3. Product Offerings
21.7.4. Key Developments
21.7.5. Financial Analysis
21.7.6. SWOT Analysis
21.7.7. Business Strategies
21.8. Novartis AG (in partnership with Cell Genesys Inc.)
21.8.1. Company Details
21.8.2. Company Overview
21.8.3. Product Offerings
21.8.4. Key Developments
21.8.5. Financial Analysis
21.8.6. SWOT Analysis
21.8.7. Business Strategies
21.9. Oncolytics Biotech, Inc.
21.9.1. Company Details
21.9.2. Company Overview
21.9.3. Product Offerings
21.9.4. Key Developments
21.9.5. Financial Analysis
21.9.6. SWOT Analysis
21.9.7. Business Strategies
21.10. PFIZER (in collaboration with WESTERN ONCOLYTICS)
21.10.1. Company Details
21.10.2. Company Overview
21.10.3. Product Offerings
21.10.4. Key Developments
21.10.5. Financial Analysis
21.10.6. SWOT Analysis
21.10.7. Business Strategies
21.11. Psivac Ltd.
21.11.1. Company Details
21.11.2. Company Overview
21.11.3. Product Offerings
21.11.4. Key Developments
21.11.5. Financial Analysis
21.11.6. SWOT Analysis
21.11.7. Business Strategies
21.12. Shanghai Sunway Biotech Co., Ltd
21.12.1. Company Details
21.12.2. Company Overview
21.12.3. Product Offerings
21.12.4. Key Developments
21.12.5. Financial Analysis
21.12.6. SWOT Analysis
21.12.7. Business Strategies
21.13. TNK Therapeutics, Inc. (Virttu Biologics)
21.13.1. Company Details
21.13.2. Company Overview
21.13.3. Product Offerings
21.13.4. Key Developments
21.13.5. Financial Analysis
21.13.6. SWOT Analysis
21.13.7. Business Strategies
21.14. Transgene/Sillajen
21.14.1. Company Details
21.14.2. Company Overview
21.14.3. Product Offerings
21.14.4. Key Developments
21.14.5. Financial Analysis
21.14.6. SWOT Analysis
21.14.7. Business Strategies
21.15. Wellstat Biologics
21.15.1. Company Details
21.15.2. Company Overview
21.15.3. Product Offerings
21.15.4. Key Developments
21.15.5. Financial Analysis
21.15.6. SWOT Analysis
21.15.7. Business Strategies
21.16. Other Market Participants
22. Key Findings
Note: This
ToC is tentative and can be changed according to the research study conducted
during the course of report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
